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Abstract
Estimating the effects of missense mutations is a problem with many important applications in
a variety of fields, including medical genetics, evolutionary theory, population genetics, and protein
structure and design. Many popular methods exist to solve this problem, the most widely used of
which are PolyPhen-2 and SIFT. These methods, along with most other popular methods, rely on
multiple sequence alignments of orthologous protein sequences. Based on the amino acids observed
in each column of the alignment, they produce a profile describing how tolerated each amino acid
is at each position. They then compare the wild-type and variant amino acids to this profile to pro-
duce a prediction.
In practice, these methods are fast, robust, and relatively reliable. However, from a theoretical
perspective, they have at least three significant shortcomings:
1. They use effects on selection as a proxy for effects on phenotype and protein structure and
function.
2. They treat each position as independent, ruling out most forms of interactions between sites.
3. They do not explicitly model the process of evolution, instead assuming that sequences we
observe more or less represent an equilibrium state.
With the recent explosion of sequencing technology, as well as the steady increase of computational
power, we are now beginning to have enough data to investigate these simplifications and see how
much they really affect the performance of these methods.
In this dissertation, I present three such investigations. First, I describe a modified predictor de-
signed to predict risk for a specific disease, hypertrophic cardiomyopathy (HCM), rather than gen-
eral seletive effect. This method achieves significantly higher accuracy than methods without such
specific domain knowledge. Next, I describe a model of pairwise interactions between sites, demon-
strating both statistically and with in vivo evidence that approximately 7–12% of disease-causing
variants may be mispredicted by these methods due to such interactions. Finally, I describe a hybrid
method that uses an alignment-based estimator to inform a parametric model of evolution, resulting
in a small but significant improvement in accuracy.
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Introduction
0.1 Motivation
In recent years, deep sequencing of genomes and exomes has begun to take the place of traditional
association studies as the method of choice for probing the landscape of human variation. The
growth of next-generation sequencing has brought with it an explosion of rare variants, with ev-
ery newly sequenced individual carrying hundreds of never-before-seen coding variants 38,141,179.
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Confidently assigning functional or phenotypic significance to these variants is a very difficult task.
Traditional human genetics methods involving observation in multiple individuals with the same
phenotype are not usually feasible for these extremely rare variants. In some genes, as many as half of
all known variants are intractible to traditional genetic evidence and considered to have “unknown
significance,” either due to the variant not having been observed in a large enough sample of indi-
viduals or due to the lack of appropriate race-matched controls for these observations 153. On a small
scale, such as for an individual patient, these unknown variants can be addressed with in vivo or in
vitro functional testing. However, it remains unfeasible to apply these experiments to the thousands
of variants observed by a large clinical lab or the hundreds of thousands of variants observed in a
population-level sequencing study.
To fill this gap, a large and growing collection of in silicomethods to predict the effects of variants
has emerged over the last decade and a half 34,101,144. These methods have seen a great deal of use in
a variety of applications, including prioritization of candidate variants and genes, characterization
of fitness effects of variants on a population level, and diagnosis of rare Mendelian disorders4,7,179.
However, these tools are still generally seen as immature, and are often compared unfavorably to
functional analysis and human genetic evidence71,153,176,205. One important reason for this is that the
accuracy of these methods remains fairly low, and the groups that produce them systematically over-
estimate the accuracy of their own methods, resulting in a reputation for unreliability72,183. Another
is that the databases containing variants of “known” effect used to train these predictors are pol-
luted with dubious annotations, which both affects the accuracy of the predictors themselves and
contributes to the perception that computational methods are unreliable 27,111.
As whole-exome and whole-genome sequencing become more and more common, the number
of variants in need of interpretation is only going to increase, and the need for accurate and trusted
tools for variant interpretation is only going to become more acute. Improving the reliability and
reputation of these tools and addressing their quirks and faulty assumptions is essential for the fu-
2
ture of the field.
0.2 TheMethod
Evolution can be seen as one enormous in vivo experiment for evaluating the effects of amino acid
changes. Changes are proposed by a stochastic mutation process, and those with negative effects
on fitness are rejected by natural selection. Thus the history of evolution contains an enormous
amount of information about which changes are tolerated and which are not. We can access part of
this history using comparative genomics, by comparing sequences from different species. The oldest
and most widely used variant effect prediction methods, SIFT and PolyPhen, have relied on this
insight since their introduction in 2001 142,172, and most widely-used methods continue to do so to
this day 101.
In general, the fixation or loss of an allele is controlled by the strength of selection against that
allele. To be precise, the probability of fixation π1 of an allele with frequency p is
π1(p) =
1  e 2Nesp
1  e 2Nes (1)
where s is the strength of selection against the allele* andNe is the effective population size† 67. If
selection is sufficiently strong (Nes  1), the allele is deterministically lost; alleles with such strong
selection acting against them should never be found fixed in any species. On the other end of the
spectrum, if selection is sufficiently weak (Nes  1), genetic drift overcomes selection against the
*Note that for the purposes of this discussion, and indeed through the bulk of this dissertation, I am ig-
noring positive selection. There are tools to detect positive selection, but for the most part positive selection is
irrelevant to the problem of variant effect prediction, as alleles under sufficiently strong positive selection fix
very rapidly and are unlikely to be found as variants requiring interpretation.
†I won’t go into the exact theoretical definition ofNe, but in most cases it can roughly be thought of as
the minimum population size at the last population bottleneck. In this case we are not really talking about a
single population, but rather a pool of many different populations over the history of evolution. Based on the
effective population sizes measured for existing vertebrate species, we can probably assume thatNe for these
ancestral vertebrate populations would have been roughly in the range of 103–106.
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allele, and the allele can become fixed stochastically with probability p just as though it were neutral.
According to this principle, any allele that is seen to be fixed in any species can be assumed to have
only weak selection acting against it.
Even at the most basic level, this principle is remarkably useful for predicting the effects of alleles
and the relative importance of sites. For example, suppose we implement the following extremely
simple classifier: any allele observed in another species in our multiple sequence alignment (in this
case we will use the MultiZ whole-genome orthologous alignment of 100 vertebrate species 103) is
benign, and any allele never observed is pathogenic. Using the HumVar dataset, a dataset of variant
annotations based on the SwissVar database and commonly used for training and testing variant
effect predictors 22,139, this extremely simple classifier correctly predicts 91% of pathogenic variants
and 63% of benign99. This should be considered a baseline for many more advanced prediction
algorithms; in some sense, the further refinements made by methods like PolyPhen and SIFT only
serve to address the 37% of benign variants that are mispredicted by this simple method‡.
The difference between this method and the basic framework used by methods like SIFT and
PolyPhen is that these methods move from the yes-or-no question of “is this amino acid tolerated at
this site?” to the concept of a “profile” of amino acid preferences at each site. Moving from a more-
preferred amino acid to a less-preferred one is likely to be damaging, while moving in the opposite
direction is probably not. The way we typically think about this profile is as the distribution of
amino acids likely to be found at the site. It’s often referred to as the equilibrium distribution of
amino acids, based on the idea that evolution is a stochastic process that we are sampling from when
we observe sequences. If the process is at equilibrium, the amino acids we observe should be drawn
from this equilibrium distribution. The most naive way of computing this distribution is simply to
count up the number of observations of each amino acid— e.g. if there is a position where we ob-
‡The 9% of pathogenic variants that are mispredicted by this simple method turn out to be much harder
to deal with. They will be discussed in greater detail below; Chapter 2 of this dissertation is aimed at character-
izing these variants.
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serve 15 sequences with valine, 4 with isoleucine, and 1 with tryptophan, we would naively describe
the preference of this amino acid site as 75% valine, 20% isoleucine, and 5% tryptophan.
There are additional adjustments that are commonly made on top of this naive method. One
very commonly used adjustment is to add pseudocounts to account for the chemical properties of
amino acids and our prior expectations about the variability of sites 80. For example, in our valine-
isoleucine-tryptophan example, we might observe that tryptophan is very chemically different
from valine and isoleucine, and its presence therefore suggests that the site is probably somewhat
tolerant of a wide variety of different amino acids. Our method might add pseudocounts of other
non-observed amino acids to account for this variability. We might also observe that leucine is very
chemically similar to valine and isoleucine, and if these two amino acids are both tolerated leucine
probably is as well. We could therefore add pseudocounts of leucine to account for the fact that our
observations of valine and isoleucine represent implied observations of leucine. Another adjustment
is to weight sequences based on their relatedness 171. This is based on the insight that two very closely
related sequences carrying the same amino acid are not really two independent observations of that
amino acid, since they are sampled from the same branch of the evolutionary tree.
This profile must then be converted to a prediction. The amino acid profile of a site is a 19-
dimensional vector§, but a prediction of pathogenicity should ideally be a one-dimensional value.
Some methods use a simple statistical model to make the conversion; for example, SIFT 142 simply
reports the expected frequency of the variant amino acid, while PANTHER-PSEC 180 reports the log
likelihood ratio of the wild-type and variant amino acids. Others, such as PolyPhen-2 2 and SNAP 18,
use the frequencies from the profile as features in various machine learning classifiers. This approach
also allows explicit incorporation of other features, such as sequence context, secondary structure
elements, or geometric features extracted from solved 3D structures. In fact, most such methods
§There are 20 different amino acid types, but the requirement that the frequencies sum to 1 restricts the
20th value, so there are only 19 independent frequencies.
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also incorporate some additional information of this kind. Even with the addition of these features,
though, the amino acid tolerance extracted from the multiple sequence alignment remains the most
informative predictive feature for all predictors that use it.
Many variations exist on this basic method, using different methods for retrieving sequences and
constructing alignments, different models to extract and adjust profiles, different sources of addi-
tional annotation, different machine learning methods, and different training datasets of known
variants. However, the basic method of using the profile of amino acids observed in evolutionary
history to estimate the amino acid tolerance of a given site is still widely used today, 14 years after the
release of the original PolyPhen and SIFTmethods. Even the latest state-of-the-art methods still use
these profile scores as major components of their predictors 25,108. It may seem strange that there has
been no major improvement on this method, considering that it is completely agnostic about bio-
logical function and protein structure, which should both be vitally important to determining the
strength of selection. Though many methods incorporate features intended to capture these factors,
these features rarely add much information on top of the profile score. This information seems al-
ready to be encoded in the profile score. After all, in some sense the profile of observed amino acid
frequencies is the result of integrating this information throughout the history of evolution.
0.3 Issues
Careful readers of the above may notice a number of places where I have hand-waved away im-
portant distinctions or discarded large swaths of established theory. This is not entirely due to my
own lack of care. There are a few important issues that most modern methods systematically ignore.
Three of these issues will motivate the three subsequent chapters of this dissertation:
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0.3.1 Deleterious vs. Pathogenic
One area where the field as a whole lacks clarity is the question of what, exactly, these tools are de-
signed to predict. Common use cases, including most of those mentioned above and most of those
proposed by the authors of these methods, primarily focus on predicting phenotypes, especially med-
ically relevant phenotypes. However, what these methods really measure is selection. In general prin-
ciple, selection is not necessarily a good proxy for phenotypic effect. There are many severe and med-
ically relevant phenotypes that may not produce very large selective effects, such as those with late
onset, reduced penetrance, or pleiotropic effects on selection 198,208. Conversely, there are many mild
or medically irrelevant phenotypes that nevertheless produce large selective effects. For example,
a spermmotility defect causing a 10% reduction in fertility should appear extremely deleterious,
despite having minimal noticeable effect on the individual’s health.
This conflation obviously has the potential to influence the accuracy of predictions, and it has
consistently been remarked on across the entire history of variant effect prediction, from the origi-
nal paper reporting the PolyPhen method (“only a small fraction of deleterious amino-acid altering
SNPs …lead to total loss of function of the affected protein, and the rest must have relatively mild ef-
fects”) 172 to the paper reporting the CADDmethod published last year (“it is at present not possible
to precisely calibrate the relationship between …estimated deleteriousness and the likelihood that a
variant is pathogenic”) 108. Nevertheless, most people who use or design these methods do not pay
much attention to this problem, since the predictions do, after all, work reasonably well. Undoubt-
edly they could work better if they made an effort to account for the relationship between selection
and pathogenicity, but it’s unclear howmuch better. Additionally, accounting for this relationship
probably requires a great deal of domain knowledge about specific genes and phenotypes, and may
not be possible on a genome-wide level.
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0.3.2 Independence of Sites
It seems reasonable enough to claim that evolution explores the range of allowed amino acids at
every site, and that we can reconstruct that range by looking at the sequences output by evolution.
However, hidden within this formulation is the tacit assumption that the range of allowed amino
acids is defined site-by-site, and that each site has a fundamentally independent profile of amino
acid preferences. In fact, the massive in vivo experiment of evolution does not just produce legal lists
of amino acids, but instead legal protein sequences, each of which folds into a three-dimensional
structure and carries out its function as a complete sequence. The two concepts are only equivalent
if interactions between sites have minimal biological importance, and the effect of multiple variants
together is almost always the sum of their individual effects. There is ample evidence in modern
genetics that interactions between sites do exist and are important, though there is some debate over
how common they really are in the history of evolution6,16,36,130.
The specific worry for variant effect prediction methods is that a nonhuman sequence might con-
tain a specific amino acid that would be pathogenic in the context of the human sequence, but is
observed in a context that compensates for its pathogenic effect. In this case, a prediction method
would be likely to incorrectly predict the variant as benign, because in fact it is observed in nature
as a benign variant. This situation, where a variant that causes a disease in human is fixed in an-
other species, is often referred to as a compensated pathogenic deviation (CPD). Several studies
have observed and commented on this phenomenon, frequently also observing that roughly 10%
of fixed differences between species are pathogenic to one of the species 30,112,115. However, despite
this relatively frequent occurrence, prediction methods generally do not make an effort to account
for CPDs. This is generally because there is no way to know a priori which interactions are impor-
tant for compensation. Without specific biological or biochemical knowledge about the protein in
question, the relevant compensation could be any position or combination of positions in the entire
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genome.
0.3.3 ParametricMethods
The idea that sequences are samples from a stochastic process of evolution is not unique to these
prediction methods; in fact, it’s a very common way of viewing evolution. There is a large and well-
developed set of models that treats evolution as a branching continuous-timeMarkov process92.
These models explicitly account for the tree structure of relationships between sequences. They also
can in priniciple explicitly account for differences and similarities between amino acids, accepting
as parameters both the relative frequencies of different amino acids and the rates of substitution be-
tween them. It may then seem odd that variant effect prediction methods do not use these state-of-
the-art models, preferring to use the heuristic methods of sequence weighting and pseudocounts¶.
In fact, there are some methods that do use these models, the most widely-used of which are phy-
loP 154 and GERP++41. They are referred to as “parametric” methods, because they deal with the
rate parameters of these models, as opposed to the profile methods, which do not have parameters
in the same sense. These methods are often used to identify funcitonal sites and conserved elements,
especially in noncoding regions4,34,79. However, they are generally not as accurate as profile-based
methods for amino acid substitutions 52,108, and therefore are not as widely used in coding sequences.
It is somewhat frustrating that parametric methods don’t perform better, since they should in
some sense be more correct than profile methods. Especially in cases where reasonably trustworthy
phylogenetic trees exist, such as for whole-genome orthologous alignments where we in principle
know the relationships of the species, it seems like we are throwing data away by not explicitly mod-
eling these trees. One easy explanation for why these methods don’t work as well is that they are
estimating the wrong quantity: instead of the profile of tolerated amino acids at a site, they esti-
¶These methods are “heuristic” in the sense that they ignore features of the theoretically correct model
and use statistical corrections for them instead. However, I do not mean to suggest that the methods are
inaccurate or incorrect; in fact, as a general rule, they seem to perform better than the full models.
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mate the rate of evolution at the site. This rate parameter should be a good indicator of evolutionary
constraint, but it does make some amount of sense that the higher-dimensional amino acid pro-
file might contain more information than a single rate score per site. In principle, it is possible to
represent the equilibrium distribution of amino acids in a parametric method— indeed, any such
method must deal with this distribution on some level, because it is a feature of the model. The re-
sults produced tend not to be too useful, though. Based on my experience experimenting with these
models, there appear to be two reasons for this:
1. It is very difficult to deal with the full 20-letter amino acid alphabet in a fully parametric way.
It requires a 2020 substitution rate matrix with 380 independent parameters, far too many
to reasonably infer using the 100-sequence orthologous alignments we typically have access
to, not to mention the seconds per site or less of computational time we typically have in
large-scale prediction tasks.
2. The likelihood surface of the 19-dimensional amino acid frequency vector seems to be very
flat. If there are two amino acids that are both clearly tolerated, it is very difficult to say what
the “correct” values for their relative preferences are. Is it 50%–50%? 80%–20%? 20%–80%?
Profile methods can safely ignore the differences between these scenarios; parametric meth-
ods can’t, because they have a dramatic influence on parameter values. In a likelihood surface
that is high-dimensional and lacks a sharp peak, likelihood methods can easily get stuck in
local maxima or fail to collect enough information to overcome the prior.
In the course of my doctoral studies, I have investigated these and other concerns about vari-
ant effect prediction methods, with the hope of pointing the way towards improvements in these
already well-established methods. The following chapters represent the results of three research
projects aimed at addressing the three specific issues described above.
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But wait: let us question a holy man,
a prophet, even a man skilled with dreams—
dreams as well can come our way from Zeus—
come, someone to tell us why Apollo rages so,
whether he blames us for a vow we failed, or sacriﬁce.
If only the god would share the smoky savor of lambs
and full-grown goats, Apollo might be willing, still,
somehow, to save us from this plague.
Homer, Iliad book 1 83
1
Variant effect prediction in the clinic
Clinical professionals have long had the intuition that computational prediction
methods do not work well enough for clinical applications71,153,176,205. Part of this problem is the ac-
tual performance of these methods, which is far below the levels required for clinical use. But a more
subtle and pervasive problem is that lack of real clinical validation. Questions like “what is the odds
ratio of this test?” simply have no answer, because most of these methods have never been tested
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with actual patients in a realistic clinical setting. This is a manifestation of the confusion between
pathogenicity and deleteriousness: these methods are reasonably good and consistent at distinguish-
ing neutral and deleterious variants, but their performance on predicting clinical phenotypes is in-
consistent, often poor, and difficult to measure in any case.
The study described in this chapter was undertaken in 2009–11 with the aim of addressing this
issue. We replaced the usual datasets used for training and validation— lists of putatively benign or
pathogenic variants derived from publicly available databases —with a list of variants classified by a
clinical genetic diagnostic lab (the Laboratory for Molecular Medicine, LMM) for clinical relevance
in a specific clinical phenotype (hypertrophic cardiomyopathy, HCM). This gave us the ability to
evaluate the method’s actual performance on a specific phenotype, which then let us attempt to
improve that performance. The clinical use case is different from the general-purpose predictor in
several important ways, which give us the possibility of improving the method’s performance:
1. We are attempting to predict a specific phenotype rather than an overall concept of “dele-
teriousness,” which allows us to incorporate specific annotations related to the molecular
mechanisms that cause that phenotype.
2. We are focusing on a small number of well-studied genes, rather than trying to make pre-
dictions that will work for the entire genome, which makes it feasible to performmanual
inspection and curation of alignments and annotations.
3. Our users do not expect instant results for any position in the genome, which allows us to
use methods that are more computationally intensive, either by precomputing results for the
relevant genes or by allowing the method to run for more time.
4. It is more important that predictions be accurate than that every variant receive a prediction,
which allows us to sacrifice coverage to improve accuracy.
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Using these insights, we developed a new predictor and measured its accuracy at 92%, a satisfac-
tory level for clinical use. The method we produced remains available online at http://genetics.
bwh.harvard.edu/hcm, and has been used as part of LMM’s variant assessment pipeline since its
completion in 2010. A study on rare variants on the FraminghamHeart Study population suggested
that our method’s accuracy was comparable to that of manual classification by experts, though it
did suggest that even manual classification may overpredict causative variants 15. However, despite
our relative success, few published studies since have attempted to create single-phenotype predic-
tion methods. Most groups that are interested in predicting variant effects continue to prefer meth-
ods that are useful across a broad range of phenotypes. This is a perfectly sensible preference, since
broadly useful methods are easier to evangelize to the medical and scientific communities and may
be of greater scientific interest. Nevertheless, our results suggest that there may a hard limit to how
accurate these methods can be without accounting for molecular features of specific phenotypes.
The remainder of this chapter originally appeared in The American Journal of Human Genet-
ics in 2011 100. Accordingly it is copyright 2011 by the American Society of Human Genetics. It is
reproduced here with permission. My primary contribution to this work was the design and imple-
mentation of the new predictive features described in 1.2.3 and the alignment pipeline described in
1.2.4, as well as major contributions to the overall study design. Supplemental materials are available
online at http://www.cell.com/ajhg/supplemental/S0002-9297(11)00012-7.
1.1 Background
DNA sequencing is quickly becoming the method of choice for clinical genetic diagnostics. The im-
provement in clinical sensitivity that sequencing provides over genotyping platforms is invaluable,
especially in disorders that show locus and allelic heterogeneity. However, there are also important
challenges presented by the use of DNA sequencing, including the difficulty of interpreting novel
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sequence variants. There is currently little standardization of variant classification in the genetics
community. Most clinics use a combination of traditional genetic methods relying on segregation
with the disease in families, frequency in controls, biochemical characterization, and evolutionary
conservation at the variant position 159. This manual classification process is time-consuming and
requires significant expert knowledge. More frustratingly, it often fails to produce a classification
at all: variants with incomplete or conflicting data are routinely classified as “variants of unknown
significance” (VUSs), and no confident classification is reported to the patient or the referring physi-
cian. In some genes, these VUSs comprise as many as one quarter to one half of all reported vari-
ants 153. This problem is only getting worse. As next-generating sequencing technologies begin to
enter widespread clinical use, the volume of novel variants should be expected to expand by several
orders of magnitude. The genetics community must begin to develop robust automated methods to
classify novel variants accurately.
There currently exist several computational tools for predicting the functional effects of genetic
variants 101,144,184. However, these tools in general were not designed for clinical use, have not been
rigorously tested on individual genes or diseases, and have not undergone any kind of validation
against well-curated datasets. Therefore, the sensitivities and specificities of these predictors are in
general ill-defined. This lack of proper validation has created the perception among medical profes-
sionals that automated predictors cannot be trusted 176. Consequently, although most geneticists
are familiar with these tools, the predictions they produce are typically not formally included in
clinical variant classification methods and are therefore not communicated to physicians via clini-
cal reports. Several studies have attempted to address this problem by validating existing predictors
against known disease-causing variants, largely arriving at the conclusion that these methods are not
yet mature enough for clinical use 53,175,176.
Variant classification pipelines that are considered mature enough for clinical use are generally
designed from the ground up with clinical use in mind, and are designed, demonstrated, and vali-
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dated using variants classified according to clinical criteria. Examples of such pipelines include the
classification procedure currently in use at the the Laboratory for Molecular Medicine (LMM), a
clinical diagnostic laboratory in the U.S., and the integrated evaluation of BRCA gene variants that
developed from the work of Goldgar et al.69. However, fully automated computational predictors
are not currently designed in this way. We therefore set out to test whether this methodology could
successfully create an automated predictor that would be useful to medical professionals as a tool
for classifying novel missense variants. We chose to target one specific disease and a limited number
of genes in which disease-causing variants might be found, so that we would be able to generate a
high-quality set of manually classified missense variants to use as the gold standard for training and
validating our predictions. We also hoped that focusing on a limited number of functionally related
genes would allow us to identify common features of these genes and commonmechanisms of dis-
ease in these genes, which would help us to make our predictor more accurate.
The disease we chose was hypertrophic cardiomyopathy (HCM), an autosomal dominant dis-
ease of the myocardium (heart muscle) with an incidence of roughly one in 500 individuals and a
largely genetic basis 190. Variants in over 20 genes are associated with HCM, with over 900 unique
variants reported in the literature, and sequencing of many of these genes can be ordered for clinical
testing in CLIA-approved laboratories. The vast majority of pathogenic variants are found in eight
genes that encode for units of the cardiac sarcomere, a contractile protein complex in the heart: beta-
cardiac myosin heavy chain (MYH7), cardiac actin (ACTC1), cardiac troponin T (TNNT2), alpha-
tropomyosin (TPM1), cardiac troponin I (TNNI3), cardiac myosin-binding protein C (MYBPC3),
and the myosin light chains (MYL2,MYL3). Sequencing of these genes yields a high number
of novel variants, mainly due to the high prevalence of private familial variants. Roughly 50% of
probands tested have a disease-causing variant in one of these genes and approximately 80% of those
are inMYH7 andMYBPC3 158 LMMunpublished data. Missense variants represent nearly all such
variants detected inMYH7 and 35% of those inMYBPC3. Missense variants exerting dominant neg-
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ative effects on the sarcomere structure represent the vast majority of all variants. The notable excep-
tion isMYBPC3, where missense variants constitute only about 35% of all variants, the remainder
being splice, nonsense or frameshift variants leading to loss of function. At the time of this study,
the Laboratory for Molecular Medicine had identified over 700 variants in HCM-related genes over
five years of testing, over half of which were novel at the time of reporting and over half of which
were missense changes. We performed a systematic manual classification of these variants, produc-
ing a final dataset of 74 missense variants with extremely confident manual classifications. Using
these 74 variants as our gold standard, we then set out to develop and validate a novel computational
method that could predict the pathogenicity of any variant in these six genes.
1.2 Methods
We created a computational method to predict the pathogenicity of a novel variant in any of the six
genes we chose to screen for HCMmutations. Our method, like other existing methods 17,142,143,203,204
and particularly the recently developed algorithm PolyPhen-2 2, integrates phylogenetic and struc-
tural information from several heterogeneous sources using a probabilistic classifier. However, un-
like these methods, it exploits the narrow focus on six specific genes known to contain variants that
cause the disease to improve the prediction strategy significantly. Also unlike these methods, it uses
variants classified according to clinical criteria of pathogenicity to train the probabilistic classifier.
The selection and classification of these variants, the features used for classification, and the training
and validation of the classifier are all described below.
1.2.1 Selection of target genes
HCM is caused primarily by variants in eight genes encoding protein subunits of the cardiac sar-
comere. We initially attempted to use all eight genes to develop our predictor. However, after con-
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structing our dataset (see 1.2.2 below), we examined the distribution of variants and found that the
final dataset contained no variants inACTC1 and only one inMYL3. We discarded these two genes
and built our classifier around the remaining six (MYH7, TNNT2, TPM1, TNNI3,MYPC3, and
MYL2).
1.2.2 Manual classification of HCM variants
We relied on LMM’s standard variant assessment pipeline to create our dataset of manually classified
variants. To ensure unbiased training and testing of our computational method, we excluded from
manual classification information that was accessible to the method such as evolutionary conserva-
tion or structural data, even though this information is currently used in the pipeline. Each variant
recieved a classification of “Pathogenic,” “Likely Pathogenic,” “Benign,” “Likely Benign,” or “Un-
known Significance” (VUS). The basic decision process we used is described below and shown in
Figure 1.1.
Pathogenic. Variants with a minimum of five informative meioses supporting familial co-segregation
with HCM, absent in healthy controls, and/or having strong functional data are classified as
pathogenic. In HCM, informative meioses typically only include individuals who are positive
for both phenotype and genotype. This level of stringency is required due to the highly vari-
able expressivity and reduced penetrance, which makes individuals without the phenotype
largely uninformative, regardless of their genotype.
Likely Pathogenic. The minimum requirement to classify a variant as likely pathogenic is absence
from race-matched controls or a large cohort of race-matched probands. The LMM has pre-
viously sequenced sarcomere genes in over 1000 HCM probands of European ancestry. Ab-
sence from this cohort was accepted in lieu of healthy control data because it serves to set
a maximum population frequency of one per the total number of probands tested. Novel
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Figure 1.1: Process used to classify variants at the LMM. This process is described in detail in 1.2. We treat the
“Pathogenic”, “Benign”, and “Likely Benign” categories as high-conﬁdence classiﬁcations for the purposes of training
the automatic classiﬁer.
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variants detected in minority populations are therefore often classified as of “Unknown Sig-
nificance” due to the lack of control cohorts or large proband data sets.
Benign or Likely Benign. Variants that are frequent in the general population (at least 3%) are clas-
sified as “Benign.” Variants present in controls at frequencies below 3% and without other
suspicion for pathogenicity are classified as “Likely Benign.”
Unknown Signiﬁcance (VUS).This class commonly includes variants for which there is insufficient
evidence to classify the variant in any of the other four categories, or variants for which the
evidence is conflicting.
Figure 1.2 shows the distribution of variants by the classification category in our database.
After applying these criteria to the complete set of variants collected by LMM, we filtered the re-
sulting dataset to exclude unconfident predictions. We excluded variants in the “Likely Pathogenic”
category, considering the classification for this category not to be stringent enough. We also ex-
cluded variants in the “Unknown Significance” category, since this category carries no clinical or bio-
logical significance. This left us with 41 “Pathogenic” variants, which we treated as truly pathogenic,
and 7 “Benign” and 26 “Likely Benign” variants, all of which we treated as truly benign. These 74
variants became our gold standard for validation of our predictor. The complete list of 74 variants is
shown in Supplemental Table S1.
There is a possibility that the manual method of variant classification may have selected variants
resulting in the most severe phenotypes, such as those seen in early onset cases, which may reduce
the utility of our classifier for less severe variants. To investigate this possibility, we used the age at
which an individual was tested as a proxy for age at onset. The distribution of ages of all probands
tested is roughly trimodal with clear peaks at less than 1 and 15 years of age and a broad distribution
centered around 50 years of age (Supplemental Figure S1). The distribution of pathogenic variants in
this population follows a similar distribution with pathogenic variants detected across a wide range
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Figure 1.2: Distribution of variant pathogenicity. We categorized 350missense variants in six genes according to the
criteria described in Figure 1.1. The three categories “Pathogenic,” “Benign,” and “Likely Benign” were treated as high-
conﬁdence classiﬁcations and used as training data for our classiﬁer (enumerated in Supplemental Table S1).
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of age groups tested. If we were indeed selecting for only the most severe, early onset phenotypes,
we would expect pathogenic variants to be over-represented in newborns and teenagers and to be
absent in late-onset cases. This does not appear to be the case and we are confident that our training
set does not only consist of pathogenic variants that lead to high penetrance, early onset disease.
1.2.3 Predictive features
We used four features in the final predictor. These features are described below.
PolyPhen-2 prediction. Our first feature was a prediction made by the existing method PolyPhen-
2 2. PolyPhen-2’s predictions integrate several sources of phylogenetic and structural informa-
tion using a Naive Bayes classifier. Its output represents a general-purpose prediction, made
without knowledge of the specific disease under consideration. The PolyPhen-2 software re-
ports a score ranging from 0 (neutral) to 1 (damaging), which represents the confidence of its
internal classifier. We used this integrated score as a single feature in our predictor.
MrBayes substitution rate score. Our second feature was the rate of evolution for each site in each
gene. We computed this using the Markov ChainMonte Carlo (MCMC) algorithm in the
MrBayes software package 161. This score took several days of computer time to calculate for
all six genes, and would not have been feasible to calculate for a genome-wide dataset.
Examples of the MrBayes instruction files we used are available as Supplemental Figure S2.
We used a function that infers site-specific evolution rates and includes them in the program’s
output. MrBayes reports the rate at positions with insufficient alignment depth as 1.000, so
all scores of exactly 1.000 were treated as missing data. We normalized this rate so that the
mean rate for each gene was 1.000.
Coiled-coil score. Our next two features took advantage of specific properties of the six target genes.
Four of the six target proteins had significant coiled-coil regions: MYH7, TNNI3, TNNT2,
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and TPM1. We used the COILS2 software to predict the tendencies of the wild-type and
mutant sequences to form coiled coils 125,126. Variants that significantly change the coiled-coil
tendency of the sequence are likely to interfere with protein function.
For each of the four proteins, we downloaded annotations from SMART to determine the
locations of coiled-coil regions 120. For any variant in a coiled-coil region, we ran COILS2 on
both the wild-type and variant sequences of the coiled-coil region that contained the vari-
ant. COILS2 outputs a score indicating coiled-coil tendency for each residue in the input
sequence, with each score depending on the entire sequence. The feature we used in the final
predictor was the magnitude of the largest single-residue change.
Protein structure comparison score. Four of the six target proteins are contractile proteins studied
in multiple conformations (MYH7 andMYL2 in ATP, ADP and nucleotide-free states;
TNNI3 and TNNT2 in Ca2+ activated and Ca2+ free states). For these four proteins, we mea-
sured the motion of each residue between the two conformations. Highly mobile residues
were considered functionally important to the conformational change, while highly immo-
bile residues were considered structurally important. Intermediately mobile residues were
scored as unimportant. We measured the size of each residue’s motion by comparing the dis-
placement of the residue to the expected probability distribution of displacements under
random thermal motion.
We used two sets of structures to compute this score. One was a set of six structures of a
three-chain scallop myosin complex, consisting of the myosin heavy chain (corresponding
toMYH7 in human heart muscle) and the two myosin light chains (corresponding toMYL2
andMYL3 in human heart muscle) 82,87. One of these structures was not bound to a nu-
cleotide (PDB ID 1KK7), two were bound to ADP analogs (PDB ID 1KK8 and 1B7T), and
three were bound to ATP analogs (PDB ID 1KQM, 1KWO, and 1L2O). The other set of
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structures was a pair of structures of a three-chain chicken troponin complex, consisting of
troponin I (corresponding to TNNI3 in human heart muscle), troponin T (corresponding
to TNNT2 in human heart muscle), and troponin C (corresponding to TNNC1 in human
heart muscle) 188. One of these structures was activated by calcium ions (PDB ID 1YTZ), and
the other had no calcium bound to it (PDB ID 1YV0).
We performed pairwise comparisons between structures that represented the same molecule
in different biological states. Pairs of structures that represented the same biological state
(such as 1KK8 and 1B7T, which both represent the ADP-bound state of myosin) were ex-
cluded, under the assumption that differences between these structures would represent
differences in the experimental preparation rather than a meaningful conformational change.
We aligned each pair of structures with LovoAlign and measured the displacement between
the alpha-carbons of corresponding residues 129.
The variance in the position of an atom in a crystal structure is given by
σ2 = B8π2 (1.1)
where B is the crystallographic temperature factor for the atom. We computed this variance
for the alpha carbon of each residue, estimating B as the average of the reported temperature
factor for that atom across the two crystal structures. We used Student’s t-test to compare
the squared displacement of the atom with its expected variance. This produced a p-value
for the observed squared displacement, with numbers close to 0 representing motion much
smaller than expected, numbers close to 1 representing motion much larger than expected,
and numbers close to 0.5 representing the expected amount of motion. Finally, scores be-
low 0.5 were subtracted from 1, so that a higher score would consistently represent a more
important residue.
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The human genes were aligned to the structures using BLAST. Each residue in the human
sequence was scored the same as the residue it aligned to. Residues that did not align to the
structures were not given a score. Only 84 human residues failed to align to the structures,
which represents 3.2% of all positions in the four proteins to which we applied this score.
1.2.4 Multiple sequence alignments
Both PolyPhen-2 and the MrBayes score described above use comparative sequence analysis as a
source of phylogenetic information. These methods take as input aligned sequences of multiple
homologous proteins, and their predictive values critically depend on the quality of the multiple
sequence alignments used. Existing computational methods, including PolyPhen-2 and SIFT, rely
on automated pipelines to construct multiple sequence alignments 2,142,143. We used the standard
automated alignment pipeline provided by PolyPhen-2, but since we only needed to construct six
alignments, we were able to inspect and adjust each alignment manually.
We noticed in our manual inspection that some of the automated alignments were of very poor
quality. The worst alignments were for the two proteins that were most highly represented in our
data set,MYBPC3 andMYH7. These proteins have numerous homologs at the domain level, aris-
ing from the multiple immunoglobulin domains ofMYBPC3 and the highly conserved myosin
motor domain ofMYH7, and the multiple sequence alignments produced using automatically se-
lected homologs are therefore of poor quality. We created new alignments forMYBPC3 andMYH7
by manually removing problematic sequences from the automatically generated alignments. This
approach allowed us to tune the alignments manually while still taking advantage of PolyPhen-2’s
automatic filtering of poor alignments and incorrect sequences. The alignments were very deep to
begin with, allowing us to remove a large number of sequences without the alignments becoming
too shallow to use.
The sequences we removed from the alignments were those that appeared to have only domain-
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level homology to the target sequences and/or did not appear to have a sufficiently similar function
to the target sequences. In other words, we attempted to create an alignment forMYBPC3 that
consisted only of forms of myosin binding protein C from various tissues and organisms, and an
alignment forMYH7 that consisted only of forms of myosin heavy chain from various tissues and
organisms. The resulting alignments were used as input to the PolyPhen-2 classifier and toMrBayes.
The sequences used are listed in Supplemental Tables S3–S6, and the resulting alignments are shown
in Supplemental Figure S3.
1.2.5 Training and validation
We trained the classifier on the manually-curated set of 74 missense variants in 6 genes. For each
variant in the training set, we computed the four features described above (PolyPhen-2 prediction,
MrBayes substitution rate score, coiled-coil score, and protein structure comparison score). The val-
ues of each feature for each variant can be found in Supplemental Table S2. The training algorithm
(Supplemental Figure S4) aims to maximize accuracy of classification while keeping the required
level of coverage. To avoid overfitting, the training algorithm uses ten-fold cross-validation (Supple-
mental Figure S5). This method splits the training data into 10 parts (6 parts of 7 samples, 4 parts of
8 samples), trains the classifier on 9 training parts and tests it on the remaining 1 testing part. It then
repeats the split-train-test procedure 10 times, each time with a different part of the data used for
testing. In order to account for the different results that would be produced by using different ran-
dom divisions of the data in this process, we ran 1,000 iterations of ten-fold cross validation, using
a different random division of the data each time. We also tested the final classifier using a leave-
one-out cross-validation strategy. The classifier assigns a prediction of “Pathogenic,” “Benign,” or
“No Call” to each variant. The “No Call” prediction is given to variants the classifier cannot predict
confidently. This category is included so that we can improve the accuracy (fraction of variants pre-
dicted correctly) of our confident predictions by sacrificing coverage (fraction of variants predicted
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as either “Pathogenic” or “Benign”) 153.
1.2.6 Feature selection
To verify that each of these four features made an important contribution, we constructed four in-
complete classifiers, each one missing one of the four features. We performed validation on each of
these classifiers as described above, and performed a random permutation test to show that the com-
plete classifier had higher accuracy than each of the incomplete classifiers. We performed 106 per-
mutations, so that the minimum P-value we could find was 10 6. Out of our four features, only the
PolyPhen-2 score had a one-sided P-value greater than this minimum, with p = 0:0544; the other
three features all had one-sided P-values less than 10 6. We also performed the same test to establish
that using manual alignments instead of automatic alignments improved the score, and found that
it did with one-sided P-value less than 10 6. Figure 1.3 shows the distributions of accuracies for each
set of features in 1,000 runs of cross validation.
In addition to the four features in our final classifier, we also tried replacing PolyPhen-2 with
the similar tools SIFT and PANTHER 142,143,180,181. We found that each performed comparably to
PolyPhen-2, though the classifier with PolyPhen-2 performed very slightly better than either, again
with one-sided P-values less than 10 6. Interestingly, though PolyPhen-2, SIFT, and PANTHER
were each far more informative individually than any other single feature, each made by far the least
individual contribution to the full four-feature classifier that included it. Evidently, the other three
features together contain enough information to make the PolyPhen-2, SIFT, or PANTHER score
largely redundant.
We also investigated the effect each feature had on coverage. This was of particular concern for
the structure pair score and the coiled-coil score, each of which is missing entirely from several genes
and regions, which could reduce the predictor’s ability to make confident classifications in these re-
gions. We found that both the structure pair score and the coiled-coil score actually increase the cov-
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Figure 1.3: Feature selection experiment. Each column shows the distribution of accuracies in 1,000 runs of cross-
validation for a classiﬁer built with a different set of features: “all features” represents the ﬁnal four-feature classiﬁer
withmanual alignments, “broken alignments” represents the four-feature without automatic alignments, and each of
the other four columns represents a three-feature classiﬁer missing the speciﬁed feature. Box plots show lower and
upper quartiles (50% conﬁdence intervals), and whiskers show 1.5 IQR ranges. The addition of each feature appears to
improve the classiﬁer, which is conﬁrmed by aMann-Whitney test.
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erage, while neither of the other features has a significant effect. This suggests that it is rare for a vari-
ant that could be scored confidently with the PolyPhen and substitution rate scores to be demoted
to “No Call” because it is missing one or both of the other features. In other words, the coiled coil
and structure pair scores tend to increase confidence where they are present rather than decreasing it
where they are absent.
1.3 Results
1.3.1 The prediction method
We created an automated method to predict the pathogenicity of missense variants in six genes
known to contain variants that cause HCM. In designing this predictor, we set out to take advantage
of the fact that we were focusing on a small set of functionally related genes to improve our predic-
tions. We identified two ways to accomplish this: first, by exploiting unique structural and biochem-
ical properties of the six target genes, and second, by applying more rigorous methods that would
be difficult to implement for large numbers of genes. With these principles in mind, we developed
a total of three predictive features, which we used in conjunction with the existing PolyPhen-2 clas-
sifier 2. Two of these features reflect specific structural properties of sarcomeric proteins. One scores
the effect of amino acid change on coiled-coil regions, while the other scores the importance of the
mutated residue to functionally important conformational transitions in ATP and Ca2+ binding do-
mains. The remaining feature is an estimated rate of evolution at the variant position. This feature
was extremely time-consuming to compute and would not have been feasible to apply to a genome-
wide dataset. It also was computed frommanually adjusted multiple sequence alignments of homol-
ogous sequences, which required human intervention to produce. These same manually adjusted
alignments were also used as input to PolyPhen-2, improving its performance. We combined these
three features and the PolyPhen-2 score using support vector regression, with our set of 74 manually
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Figure 1.4: The automated prediction process. For each variant, we computed four features and combined them using
support vector regression. We trained this classiﬁer on the high-conﬁdence variants classiﬁedwith clinical data, and
validated the classiﬁer against the same data using ten-fold cross-validation.)
classified variants as a training set. The complete method is presented graphically in Figure 1.4.
We also experimented with a small number of alternative features. The most notable among
these were a different estimate of the rate of evolution computed using a genomic alignment of 46
vertebrate species, and several of the individual phylogenetic scores used as predictive features in
PolyPhen-2. Addition of these features did not improve the performance of the predictor.
1.3.2 Validation of the method against manually classified variants
Given the small size of our gold standard dataset (74 variants), the choice of training and valida-
tion method was important. Because we had so few variants, it was not feasible for us to use the
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simplest validation method of splitting the dataset in half and using one half for training and the
other for testing. Instead, we applied ten-fold cross validation, which is the accepted procedure in
such cases (see 1.2.5). We ran this validation process a total of 1,000 times to obtain median results
and confidence intervals. Figure 1.5 shows the results of this validation for six different classifiers
at different levels of coverage and accuracy. We used the bottom row, highlighted in red, as our fi-
nal classifier. The method predicts each variant as “Pathogenic,” “Benign,” or “No Call,” with the
“No Call” result meaning that the predictor is not sufficiently confident to report a prediction. The
median accuracy for covered variants for the most accurate classifier (the fraction of correct predic-
tions out of all “Pathogenic” and “Benign” predictions, while disregarding “No Call” results) was
92%, with a 95% confidence interval of 83%–98%. The median coverage (the fraction of variants
that were predicted as either “Pathogenic” or “Benign”), was 57%, with a 95% confidence interval of
49%–64%; in other words, the median classifier reported “No Call” for 43% of variants. The median
sensitivity for covered variants (the fraction of variants manually classified as pathogenic that were
predicted as “Pathogenic,” excluding those predicted as “No Call”) was 94%, with a 95% confidence
interval of 83%–98%. The median specificity for covered variants (estimated as the fraction of vari-
ants manually classified as benign that were predicted as “Benign,” excluding those predicted as “No
Call”) was 89%, with a 95% confidence interval of 83%–98%. The median odds ratio for a predic-
tion of “Pathogenic” (the odds of a pathogenic variant being classified as “Pathogenic” divided by
the odds of a benign variant being classified as “Pathogenic”) was 10, with a 95% confidence interval
of 4.0–infinity (no upper bound could be set since more than 5% of trials had no false positives).
The median odds ratio for a prediction of “Benign” (the odds of a benign variant being classified as
“Benign” divided by the odds of a pathogenic variant being classified as benign) was 9.9, with a 95%
confidence interval of 4.6–21. Leave-one-out cross validation also resulted in highly similar estimates
of all these quantities.
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Figure 1.5: Results of cross validation. Rows contain median ten-fold cross validation results for the gold standard
dataset at different levels of coverage. Horizontal bars correspond to different levels of coverage andmedian valida-
tion coverage and accuracy levels are indicated. ‘True Positives’ are variants manually classiﬁed as “Pathogenic” that
our method predicted as “Pathogenic.” ‘True Negatives’ are variants manually classiﬁed as “Benign” or “Likely Benign”
that our method predicted as “Benign.” ‘False Positives’ are variants manually classiﬁed as “Benign” or “Likely Benign”
that our method predicted as “Pathogenic.” ‘False Negatives’ are variants that manually classiﬁed as “Pathogenic”
that our method predicted as “Benign.” ‘Uncovered’ are variants without a prediction (“No Call”). The bottom-most
coverage level, indicated in red, was used for our ﬁnal predictor.
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1.3.3 Comparisonwith general-purpose methods
Since our predictor bases its predictions in part on predictions of the existing general-purpose method
PolyPhen-2, we investigated whether our predictor was a significant improvement over the PolyPhen-
2 predictor without our modifications and other general-purpose methods. In order to investigate
this, we tested PolyPhen-2, SIFT, and PANTHER on the same dataset. We applied the same ten-
fold cross-validation method with each of these three scores as the only predictive feature. We found
that all three general-purpose scores had comparable performance on this dataset: PolyPhen-2’s me-
dian cross-validation accuracy was 70% (95% confidence interval 60%–77%), SIFT’s was 74% (95%
confidence interval 64%–83%), and PANTHER’s was 68% (95% confidence interval 56%–79%). All
of these estimates are much lower than the accuracies reported for these methods, which may reflect
features of this dataset. Our specialized predictor, on the other hand, had a median accuracy of 92%
(95% confidence interval 83%–98%), as reported above. A permutation test showed that all three
general-purpose predictors performed worse than our specialized predictor, with one-sided P-values
of less than 10 6.
1.3.4 Predictions for variants without confident classifications
The ultimate goal of our predictor is to provide accurate predictions for variants that are not confi-
dently classified by manual methods. This will not be possible if there is some systematic biological
difference between the confident and unconfident classifications, such as a difference in penetrance,
severity, or mechanism of disease. To determine whether this is the case, we applied our method to
a low-confidence dataset, the set of missense variants that did not meet the confidence criteria to be
manually classified as truly pathogenic or benign (Figure 1.6). Of the missense variants manually
classified as “Likely Pathogenic,” 80% of those for which a prediction was made were predicted as
“Pathogenic.” This is consistent with the expectation that most of these “Likely Pathogenic” vari-
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Figure 1.6: Results for low-conﬁdence dataset. Columns indicate, for each class of variants, the number of predictions
in predicted categories produced by the ﬁnal classiﬁer.)
ants are indeed pathogenic. It is also consistent with the expectation that the fraction of variants
predicted as “Pathogenic” in this set is lower than for variants manually classified as confidently
pathogenic. Among variants manually classified as “Unknown Significance,” 70% of those for
which a prediction was made were predicted as “Pathogenic.” Since these variants have been iden-
tified in individuals diagnosed with HCM, there is a higher a priori likelihood that they are indeed
pathogenic, although we have no way of knowing what the true fraction should be. The fraction
of variants predicted as pathogenic remains lower in the “Unknown Significance” set than in the
“Likely Pathogenic” set, which is consistent with what would be expected.
We also used the low-confidence dataset to generate an independent estimate of the predictor’s
coverage. We found that the predictor made a prediction for 60% of low-confidence variants, which
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is well within the confidence interval of 49%–64% for the estimated coverage on the gold standard
variants.
Discussion
We developed and clinically validated an automated method to predict the pathogenic effect of
missense variants that might cause HCM. Unlike current commonly used methods, our predictor
has been validated against high-confidence manually curated data. This enabled us to estimate its
specificity and sensitivity for the specific task of predicting HCMmutations, which will allow its
predictions to be incorporated into clinical reports to health care professionals as one piece of evi-
dence supporting a variant classification. Although this tool adds little for variants whose clinical
significance is already supported by strong genetic and/or functional data, it will add value for those
variants that had little or no prospect of ever being supported by solid family studies or large scale
healthy control studies. Importantly, our classifier is particularly helpful for variants identified in
minority populations, where healthy control cohorts, one of the pillars of traditional variant classifi-
cation, are typically unavailable.
To maintain high accuracy, it was necessary to sacrifice coverage, i.e. the proportion of variants
for which a prediction is made 153. As shown in Figure 1.5, an increase in coverage is accompanied by
a rapid decline in accuracy. A method attempting to predict every variant as either pathogenic or
benign could not achieve levels of accuracy acceptable for clinical use. We estimated the coverage of
our predictor at 57%, with a 95% confidence interval of 49%–64%. We believe this level of coverage is
still above the threshold of clinical usefulness. For comparison, note that out of 350 LMMmissense
variants in the six target genes, only 74 met the criteria for high-confidence manual classification,
giving the manual classification process a coverage of only 21%. Note also that our method covers a
different set of variants than the manual classification process, including 59% of the variants that the
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manual classification classifies as “Unknown Significance.”
The most important limitation of our automated prediction method stems from the size of the
training data set. In general, training on small data sets may lead to overfitting of automated clas-
sifiers. An overfit classifier may be highly accurate on the training data but much less accurate on
new data. We applied several safeguards against overfitting during training and validation. These in-
cluded limiting the number of features in the classifier, using only features that we expected a priori
to be informative, and performing cross-validation to calibrate parameters and estimate accuracy. In
this way we hope we have avoided excessive overfitting in our final predictor.
It is important to point out that this method may not accurately predict the effect of those mis-
sense variants that exert their effect partially or fully though affecting mRNA splicing. This is true
for all currently available tools of this kind, including PolyPhen-2, SIFT, and others. For example,
the MYBPC3 Glu258Lys variant was confidently manually classified as “Pathogenic” but was incor-
rectly classified as “Benign” in several runs of cross validation (though not in the final predictor).
ManyMYBPC3 variants affect splicing and there is evidence that the Glu258Lys variant is disease-
causing via this mechanism. The underlying cDNA alteration is c.772G>A, which affects the last
base of exon 6. This position is known to be part of the splice consensus and 5 different splice pre-
dictors (SpliceSiteFinder-like, MatEntScan, NNSPLICE, GeneSplicer and Human Splice Finder; see
Supplemental Figure S6) predict an impact on splicing. This is supported by evidence showing that
this may result in skipping of exon six 5,128. Therefore, the conservation of the nucleotide and not the
amino acid at this position is essential, possibly explaining a misprediction by our predictor. This is
a limitation of this method and clearly lends itself to future improvement and generation of tools
that incorporate a splice assessment.
It is also important to point out that clinical laboratories are typically aware of this limitation.
Novel variant assessment is a lengthy and complex process that relies on a large collection of differ-
ent computer tools in combination with traditional genetic evidence such as familial segregation
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with disease and absence from race-matched healthy controls. All evidence is taken into account to
synthesize a final probability for pathogenicity. In our laboratory, a splice assessment is performed
for every variant, regardless of whether it changes an amino acid or not, and a benign prediction by
this predictor would not lead to a final classification as “Benign”, particularly not for genes where
pathogenic splice variants are known to be common.
This example that illustrates that this predictor or any other predictor developed with this method-
ology should not be used as a sole foundation for a diagnosis but rather be used in combination with
other lines of evidence in agreement with ACMG and IARC recommendations 153,159. We envision
future development of a single probabilistic classifier that would automatically combine heteroge-
neous factors such as familial segregation, frequency in controls, functional evidence and computa-
tional predictions following early work in this area.
1.4 Conclusion
We have addressed the problems that prevent automated predictors from being widely used in ge-
nomic medicine by developing a custom-tailored predictor specifically designed for clinical use. Our
analysis suggests several important considerations that can increase the accuracy of computational
methods. Manual adjustment of multiple-sequence alignments and time-consuming computational
methods of molecular evolution are feasible when focusing on a small set of genes and may improve
predictions that use comparative sequence analysis. Exploitation of specific structural properties of
proteins also becomes feasible when focusing on a specific disease. Most importantly, a highly accu-
rate manually-curated dataset is necessary to train and validate an accurate predictor, and this level
of validation enables clinical laboratories to include it as part of their variant assessment processes.
Where previous studies have concluded that existing tools are not mature enough for clinical use, we
believe that our tool is ready for clinical use now, in combination with other sources of information.
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Our collaborating clinical laboratory, the Laboratory for Molecular Medicine, has already begun to
use our predictor as a source of information about HCM variants, and we look forward to helping
additional laboratories do the same. Our study focused on HCM, but we believe that our approach
is general and that analogous methods can be constructed for many other diseases where genetic
testing is an important part of the diagnosis. In the future we expect to work with additional labo-
ratories and on additional diseases to expand the use of automated predictors in genomic medicine
and simplify the problem of interpreting novel variants.
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Who are you? where are you from? your city? your parents?
I’m wonderstruck—you drank my drugs, you’re not bewitched!
Never has any other man withstood my potion, never,
once it’s past his lips and he has drunk it down.
You have a mind in you no magic can enchant!
Homer,Odyssey book 10 84
2
Compensation of disease alleles
It is well established that human disease mutations can become fixed in other species
due to compensations present elsewhere in that species’ genome. The fixation of pathogenic mu-
tations due to compensation is referred to as compensated pathogenic deviation (CPD), a name
coined in the 2002 paper by Alexey Kondrashov et al. that first described the phenomenon 112. This
paper established that approximately 10% of fixed differences between two species are pathogenic
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to one of them, a result later reproduced in flies 115. Many other studies since have recognized the
phenomenon and examined the properties of these compensations 8,30,55,60.
Despite broad recognition that pathogenic variants can and do appear in other species, existing
methods to predict the effects of variants mostly ignore this phenomenon, assuming that a variant
observed in another species is likely to be benign 101. There are good reasons for this approach, of
course: with no biochemical or biological insight into the specific genes and phenotypes involved,
there is no obvious way to go about detecting compensation, especially considering that we expect
about 90% of variants appearing in other species to be truly benign. Still, it is a little troubling that
no previously published study has attempted to estimate the impact CPDs have on the accuracy of
prediction methods* or to propose a framework for detecting CPDs.
Using the recently available whole-genome orthologous multiple sequence alignment of 100
vertebrate sequences fromUCSC 103 and the ever-increasing number of variants with annotated
pathogenic effects, we created a dataset of likely CPDs that can be used to address both of these
questions. To the first point, we estimated the prevalence of CPDs among known human disease
mutations in the range of 7%–12%. To the second, we observed a different distribution among
species for neutral variants and CPDs, leading us to develop a statistical model of the fixation and
genetic structure of CPDs. We used this model to propose an experiment design for detecting CPDs
in vivo, and produced evidence for three specific cases in a zebrafish model. We also developed an in
silico predictor based on our model. As mentioned above, it remains true that any variant seen in an-
other species is far more likely than not to be benign; however, our predictor can at least distinguish
between variants that are likely to be benign and variants that are almost certain to be benign, effec-
tively adding additional levels of gradation to the “benign” classification. This classifier is available
*Note that the 10% number from Kondrashov et al. is the number of fixed differences between species
that are pathogenic, while the impact on prediction accuracy is determined by the reverse of this number—
the number of pathogenic variants that appear in other species. Some confusion about this point exists in the
literature, and some published papers conflate these two numbers.
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online at http://genetics.bwh.harvard.edu/cpd.
The remainder of this chapter is, at the time of this writing, in press inNature99. It is reproduced
here with permission. Supplementary material will be published online, but is included in this dis-
sertation in appendix A. My primary contributions to this work are the design and implementation
of the bulk analysis of multiple sequence alignments described in 2.2, the statistical model of CPD
fixation described in 2.3, and the CPD predictor outlined in 2.5.
2.1 Background
Understanding the nature and prevalence of genetic interactions has the potential to inform the
evolutionary forces that act on specific protein residues, protein complexes and, more broadly, the
evolution of genomes. Some recent studies have reported that interactions are ubiquitous and con-
tribute significantly to the evolutionary landscape 16,91,124,192,while others found that interactions
are rare and that protein evolution can be modeled without taking them into account 39,81,130. Even
among those who agree that interactions are important, the architecture of these interactions re-
mains unclear: some studies find distinct interactions between two or three sites 36,60,75, while others
propose a complex interaction network, effectively responding to aggregate properties of the entire
protein or the entire genome 31,91,193.
One practical utility of comparative genomics has been highlighted by our emerging appreciation
of the large number of rare variants in humans and the difficulty in inferring their contribution to
disease phenotypes 34. To prioritize variants of interest, their frequency in control populations and
their evolutionary conservation have become two prominent filters 179. Conserved regions are con-
sidered more likely to be biologically important and intolerant of variation4,11,122; programs such as
PolyPhen 2and SIFT 165have employed this principle to predict the functional effects of variants in
both the research and clinical setting7,34,101. Although clearly useful, these strategies are constrained,
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in part because they do not take into consideration the genomic context of the mutated allele. An al-
lele can appear to be damaging in one sequence yet be neutral in an orthologous sequence of another
species. This phenomenon, referred to as compensated pathogenic deviation (CPD), contributes
an unknown, but potentially significant, number of false negatives to the evaluation of functional
sites 101,112,115.
2.2 Prevalence of CPDs
To examine the prevalence of CPDs, and to identify such sites, we used comparative genomics on a
genome-wide scale. A typical, non-CPD allele should cause the same phenotype in any orthologous
sequence, regardless of genetic background. By contrast, when a variant that causes human genetic
disease is found in a wild-type (wt) orthologous sequence, it is likely that the genetic background of
that species exerts a compensatory effect on such a variant: it suppresses the phenotype otherwise
caused by the variant, and thus protects the variant from negative selection60,112,115,167. Previous stud-
ies have used this insight to quantify the fraction of interspecies substitutions that are CPDs at ap-
proximately 10%, regardless of the distance between the two species 112,115,167. Other studies have also
reported estimates of the inverse value, namely the fraction of pathogenic variants that are present
as CPDs in other species, ranging from 2%–18%, depending on the exact sequences and method-
ologies 30,55. We set out to produce a new estimate of this value, taking advantage of the availability
of large datasets of sequence variants and multiple sequence alignments. We collected two datasets
of missense single-nucleotide variants (SNVs), annotated as either benign, or implicated in human
disease, derived from two databases, one based on the literature (“HumVar”)2,22,139 and one based
on reports from clinical genetic laboratories and investigator-initiated submissions (“ClinVar”) 118.
Although the two databases are not fully independent, since some variants are present in both from
the same source, the majority of pathogenic variants were listed in one or the other (Figure 2.1A).
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Table 2.1: Fraction of likely pathogenic mutations in humans considered CPDs according to different ﬁltering
paradigms. Values represent the fraction of variants for which an alignment could be retrievedwhere the variant
amino acid is present in an ortholog sequence; error ranges are Jeffreys 95% conﬁdence intervals.
Unfiltered
Alignment
(MultiZ)
High-
Quality
Alignment
(MultiZ)
Mammalian
Subset
(MultiZ)
Multiple
Species
(MultiZ)
EPO Align-
ment
HumVar 12:0% 0:5% 11:5%0:5% 6:7%0:4% 6:1% 0:3% 7:5%0:4%
ClinVar 10:2% 0:7% 9:9%0:7% 5:6%0:5% 4:7%0:5% 6:5%0:6%
HumVar + ClinVar 9:3% 1:0% 8:5% 1:0% 5:3% 0:8% 3:9%0:7% 5:5% 0:9%
HumVar + ClinVar
+ ESP
7:5% 1:0% 7:0% 1:0% 3:8%0:7% 3:0%0:6% 4:0%0:8%
In total, these datasets comprised 69,905 human missense mutations across 13,040 genes. We then
compared this dataset to multiple sequence alignments of orthologous proteins from 100 vertebrate
species 103. As expected, we found the mutant residue for a large number of likely neutral human
variants to be fixed in orthologs. However, the number of pathogenic missense variants found in
orthologs (CPDs) was surprisingly high: 5:6%  0:5% of ClinVar and 6:7%  0:4% of HumVar
were found in the alignment of mammalian species. For all vertebrates, these numbers increase to
10:2%  0:7% and 12:0%  0:5%, respectively, for a combined rate of 11:7%  0:4% (Table 2.1),
although the alignments for non-mammalian vertebrates are not supported by synteny.
Mindful of the possibility that our allele set was contaminated with false pathogenic annota-
tions 27,111, we applied a number of filtering steps with the goal of estimating the range of CPD inci-
dence in humans. These steps included cross-referencing HumVar and ClinVar variant annotations
with each other and with population frequency data 179, filtering based on alignment quality 3, using
alternate alignment methodologies 57, and requiring presence in multiple species (Table 2.1; Supple-
mentary Note). In addition to removing false positives, some of these filters did remove bona fide
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recessive alleles (since we did not allow carriers), as well as disease variants with incomplete pene-
trance, even though this class of alleles is, by definition, sensitive to genomic context and thus likely
to be affected by compensation49,68. Nevertheless, all filtering steps retained a substantial number
of variants (Table A.1); post hoc manual evaluation and literature review yielded numerous robust
examples of alleles that drive acute genetic disorders (Table A.2). Importantly, including only vari-
ants that pass all filtering steps and are detected in more than one vertebrate, we still predict that the
minimum estimate of CPDs in human patients is 3% (Figure 2.1B). This is consistent with previ-
ous analyses, which have found that stringent filtering does not change the observed properties of
CPDs significantly 55,167. As a final test, we extracted post hoc likely pathogenic alleles from three dif-
ferent sources, each of which used independent means for assessing pathogenicity in acute pediatric
disorders: the 183 non-synonymous pathogenic alleles reported recently in the Deciphering Develop-
mental Disorders (DDD) study 56; the 161 curated non-synonymous alleles from the genes that cause
neuronal ceroid lipofuscinosis 113and the 49 alleles implicated as recessive drivers of Bardet-Biedl syn-
drome that have also been annotated functionally in vivo 206. Considering our stringent mammalian
alignments only, the CPD rates were 9%, 5.5% and 4% respectively. Of note, when we only consid-
ered de novo alleles fromDDD in the mammalian alignment exclusively and absent from control
databases, the most conservative boundary for CPD incidence from this analysis remains at 3%. We
performed several additional analyses to rule out other possible sources of bias (see Supplementary
Note, Tables A.3, A.4, A.5); these analyses were also consistent with previously reported properties
of CPDs8,55.
2.3 Structure of Genetic Interactions
We next turned to the question of the structure of the genetic interactions underlying such sites. In
broad terms, there are two possibilities: suppression of the disease phenotype may be the result of a
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Figure 2.1: Distribution of variants found in sequence alignments. A) Venn diagram showing sizes and overlap of the
ClinVar andHumVar datasets of human disease variants, and howmany are found in themultiple sequence alignment.
B) Illustration of the estimated number of human disease variants found in the alignment. The smallest estimate (3.0%,
dark blue) comes from using the intersection of both variant datasets, requiring the variant be absent from 6,503
human exomes, and ﬁltering out alignments with low quality scores. With anymethodology, at least 88% of human
disease variants (grey) are not found in the alignment. C, D) Illustration of potential mechanisms for the occurrence
of compensated pathogenic mutations in evolution. Branches where the variant is ﬁxed are purple; branches where
the variant is pathogenic are red. In panel C, the variant is present neutrally in an ancestral population, but is lost in
the primate branch. Subsequent substitutions cause the ancestral allele to become pathogenic. In panel D, the variant
is pathogenic in the ancestral population, but mutations in a non-human branch cause it to become tolerated, and it
arises later bymutation and becomes ﬁxed.
44
small number of discrete compensatory substitutions; or suppression may be caused by global shift
in the properties of the gene, or even of the whole genome, caused by a large number of discrete sub-
stitutions that, individually, have small effects. These two models have different ramifications for
detecting the mechanism(s) that drive CPDs. If only a small number of substitutions are involved,
we can attempt to identify individual cis-compensatory substitutions by studying the co-evolution
of the CPD residue with other residues within the target protein. By contrast, this kind of experi-
ment is virtually impossible if multiple genes or the entire genome is involved.
The difference between these two models should be visible in the distribution of CPDs among
orthologous sequences. In the course of evolution, variants arise stochastically through a Poisson
process, where the expected amount of evolutionary time required to produce a given substitution is
distributed exponentially. For a CPD, however, the distribution should be different. This is because
the presence of a CPD also mandates the presence of all the compensatory substitutions necessary
for the CPD to be rendered neutral. As such, the expected evolutionary time required to produce
a CPD is the sum of the times required to produce each necessary compensatory substitution, fol-
lowed by the time required to produce the CPD itself.
Previous studies have proposed different processes by which CPDs can arise. The most plausi-
ble option is a neutral mechanism, where the compensatory substitutions are themselves neutral
and arise and fix neutrally before the pathogenic substitution appears (Figure 2.1C, D; Figure 2.2A).
In this case, the time required for each substitution to arise is given by an exponential distribution,
and the time for all compensatory sites to arise is approximated by the convolution of multiple ex-
ponential distributions (or a gamma distribution, in the special case where all these exponential
distributions are identical). The number of exponential distributions included in the convolution
corresponds to one plus the number of compensatory substitutions required, and it can be inferred
from the shape of the distribution (Figure 2.2B).
Although the actual evolutionary time separating two sequences is not observable directly, we
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Figure 2.2: Relationship between variants and evolutionary distance. A)Model for ﬁxation of CPDs. Neutral changes
(Xs) arise neutrally over evolutionary time. Some of these (blue) compensate for alleles that would otherwise be
pathogenic. Once k of these compensatory changes have ﬁxed, the CPD (red) can ﬁx neutrally. B) The relationship
between evolutionary distance and the number of variants observed in the alignment is expected to be different for
individual benign variants (black) and pathogenic variants with different numbers of compensations (blue: one, red:
two, cyan: ﬁve, magenta: ten). C, D) Observed distribution of missense variants annotated as neutral (C) or pathogenic
(D) in the HumVar dataset and present in vertebrate orthologs (bars), withmaximum likelihood ﬁts (black lines) and
95% conﬁdence bands (gray shading). Panel D corresponds to a ﬁtted value for k of 1:44 0:07.
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can approximate it using sequence distance (one minus sequence identity).We therefore plotted the
number of missense variants observed as a function of sequence distance for neutral variants and
for CPDs. Qualitatively, the shapes of both distributions match theoretical expectations. The two
distributions are remarkably distinct from each other (p = 1:6  10 68, Kolmogorov-Smirnov 2-
sample test; see Tables A.6, A.7), providing additional evidence that variants annotated as neutral
and variants annotated as pathogenic represent biologically distinct classes. Additionally, the ob-
served distribution of CPDs is weighted toward shorter evolutionary distances, as expected if most
CPDs require only a small number of individual compensatory substitutions, and does not resemble
the normal distribution expected if most CPDs require many individual compensatory substitu-
tions (Figure 2.2B, D). To obtain a more precise estimate of the number of compensatory substitu-
tions, we used maximum likelihood to fit several versions of the convolution-of-exponentials model
with several different combinations of variant datasets and alignment strategies (Figure 2.2C, D; see
methods and Tables A.6, A.7). Most versions of the model fit best as the convolution of approxi-
mately two exponential distributions, supporting a mechanism whereby the majority of CPDs are
compensated by simple pairwise interactions. Additionally, most models reported similar rates of
evolution for neutral variants, CPDs, and compensatory variants, suggesting that the target size for
compensatory changes is small. We repeated these analyses with multiple different variant datasets
and alignment strategies, finding similar results each time (Figure A.1, Table A.8).
These analyses predict that most CPDs could be rescued by one large-effect compensatory substi-
tution. We tested this prediction experimentally. We posited that each vertebrate sequence that in-
cludes a CPD should also include its cis-compensatory allele. Therefore, every amino acid difference
between the human sequence and the sequence of the ortholog(s) containing a CPD is a candidate
compensatory substitution. Given the practical constraints of examining all possible compensatory
substitutions in macromolecular complexes, we focused on substitutions within the same gene as
the CPD. This restriction is supported by previous observations, wherein 90% of compensatory
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substitutions found in eukaryotes lie within the same gene as the pathogenic substitution for which
they compensate 156.
2.4 In Vivo Validation of CPDs
Scanning our list of candidate CPDs, we noted two alleles in genes involved in ciliopathies: a p.N165H
encoding change in BBS4 and a p.R937L variant in RPGRIP1L, which contribute pathogenic alle-
les to Bardet-Biedl syndrome andMeckel-Gruber syndrome, respectively 105,106. These alleles were
prioritized to test our predictions for several reasons: a) those disorders have a severe effect on repro-
ductive fitness; b) previous studies have established loss-of-function zebrafish phenotypes rescuable
by human mRNA for both genes 106,206; c) in vivo complementation with each allele has indicated
both of them to be deleterious to the function of the human protein 106,206; and d) we observed
multiple species with the human mutant allele fixed: six species for BBS4 165H and four species for
RPGRIP1L 937L (Figure 2.3A, B); for this reason, both alleles were predicted to be benign by several
computational methods (PolyPhen-2, SIFT, MutationAssessor).
Comparative genomic analysis of BBS4 and RPGRIP1L identified nine candidate sites in human
BBS4 and 32 candidate sites in human RPGRIP1L (519 aa and 1315 aa of target sequence respectively;
Table A.9) that co-evolved with the deleterious allele. To test each site, we took advantage of the es-
tablished convergent extension (CE) defects induced by morpholino (MO)-mediated suppression
of bbs4 or rpgrip1l in zebrafish embryos 106,206. Consistent with previous observations, suppression
of bbs4 or rpgrip1l induced CE defects in 80% and 50% of embryos respectively (50-100 embryos,
performed in triplicate, blind scoring; Figure 2.3C–E). Co-injection of MOwith human wt mRNA
rescued this phenotype, whereas injection with human mutant mRNA showed no improvement
(Figure 2.3D, E). We next tested the entire candidate complementing allelic series for each gene. For
BBS4, the introduction of two of the nine candidate residues in cis with the 165H-encoding mRNA
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Figure 2.3: Compensatorymutations rescue pathogenic alleles in BBS4 and RPGRIP1L. A) The pathogenic BBS4
165H allele is ﬁxed in six species. Secondary sites 160, 163, and 366 are possible sites of complementation. B) The
pathogenic RPGRIP1L 937L allele is ﬁxed in four species. The 189L, 193L, and 961T alleles are present in all four
species. C) Examples of zebraﬁsh convergent extension phenotypic groups. D) Human RNA containing both the BBS4
165Hmutation and either the 366R or 366Tmutation can rescue themorphant phenotype, whereas RNA containing
the 165Hmutation alone cannot. E)Mutation of 189L, 193L, or 961T, in the background of 937L RPGRIP1LmRNA,
is able to rescue the loss of function observed in 937L RNA. Signiﬁcance determined byχ2 test; see Table A.9 for raw
data.
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ameliorated the phenotype in a manner indistinguishable from wt mRNA. Strikingly, both com-
plementing alleles affected the same amino acid and were specific with regard to the compensatory
changes: the 165H/366N or the 165H/366S behaved as functionally null, whereas 165H/366R was
indistinguishable from wt; 165H/366T converted the functional null to a hypomorph (Figure 2.3D;
Figure A.2A).
We observed a similar pattern for RPGRIP1L, despite the larger number of candidate comple-
menting sites. Testing each of the 32 candidates identified three complementing events, two of
which map to the same region: 937L/189L, 937L/193L and 937L/961T (Figure 2.3E; Figure A.2B).
Crucially, testing each complementing allele individually on wt background human mRNA showed
them to be either extremely mild for BBS4 or benign for RPGRIP1L (Table A.9). Finally, compar-
ative genomic analysis of these sites showed that these data could explain the tolerance of the RP-
GRIP1L 937L-encoding allele in all four species and of the BBS4 165H-encoding allele in four of the
six species (Figure 2.3A, B).
The above analysis is limited by its retrospective nature. We therefore tested the usefulness of our
model in the context of ab initio gene discovery. We have initiated recently a whole exome sequenc-
ing (WES) and functional testing paradigm to accelerate gene discovery and diagnosis in young
children with suspected genetic disease: The Duke Task Force for Neonatal Genomics (TFNG).
Patients who display anatomical phenotypes amenable to functional modeling in zebrafish are eval-
uated by trio-basedWES and have candidate alleles tested systematically by in vivo complementa-
tion 104.
As part of the TFNG, we enrolled a 17-month-old female with an undiagnosed neuroanatom-
ical condition hallmarked by microcephaly (Figure 2.4A). We filteredWES data to retain non-
synonymous and splice variants with a minor allele frequency below 1%, and we conducted a proband-
centric trio analysis. This strategy yielded four candidates: de novo missense changes in two genes,
BTG2 andNOS2; and autosomal recessive missense variants in TTN and LAMA1. Testing of an
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unaffected female sibling excluded LAMA1; and we considered TTN, a known autosomal domi-
nant cardiomyopathy locus 133, to be an unlikely driver.
To investigate the allele pathogenicity of the BTG2 (p.V141M) andNOS2 (p.P795A) changes, we
studied btg2 and nos2 in zebrafish embryos. Reciprocal BLAST identified a single zebrafish btg2 or-
tholog and two zebrafish nos2 orthologs. We injected splice-blockingMO or translational-blocking
MO (sb-MO and tb-MO; Figure A.3) into wt zebrafish embryos (3 ng; n=80 embryos/injection).
Given the microcephaly in the patient, we scored for head size defects at 4 days post-fertilization
(dpf) by measuring (blind to injection) the anterior-posterior distance between the forebrain and
the hindbrain (Figure 2.4B). For nos2a/bMO-injected embryos, we saw no appreciable differences
at the highest dose injected (8 ng for nos2a/b sb-MOs; Table A.10). In contrast, we found a signif-
icant reduction of anterior structures in btg2 morphants (p<0.0001; Figure 2.4B, C). Co-injection
of wt human BTG2mRNAwith tb-MO resulted in significant rescue (p<0.0001; Figure 2.4C). In
contrast, upon blind scoring of embryos injected with either wt or 141M-encoding mRNA (in tripli-
cate), we found that 141M was significantly worse at rescue than wt (p<0.0001; Figure 2.4C).
BTG2 is a regulator of cell cycle checkpoint in neuronal cells at the G1 to S phase 138 and is strik-
ingly intolerant to variation in humans (Exome Variant Server, EVS). To gain insight into the un-
derlying cause of microcephaly in btg2 morphants, and to test the pathogenicity of the discovered
allele by a different assay, we performed antibody staining at 2 dpf (a time prior to the manifesta-
tion of microcephaly). We marked post-mitotic neurons in the forebrain with HuC/D, and we
scored (blind, in triplicate) based on an established paradigm 13. btg2morphants displayed a signif-
icant decrease in HuC/D staining (97% vs. 50% of embryos with normal expression/localization;
controls versus MOs, respectively; p<0.0001; Figure 2.4D, E). This defect was rescued withWT
BTG2mRNA (p<0.05); but could not be ameliorated by 141M-encoded mRNA co-injection (Fig-
ure 2.4D, E). Importantly, co-injection of btg2 tb-MOwith two rare control EVS alleles (p.A126S
and p.R145Q, each present in 1/13,006 and 1/12,994 chromosomes, respectively) resulted in rescue of
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Figure 2.4: A de novoBTG2 p.V141M encoding allele causesmicrocephaly. A) Pedigree of DM048. Chromatograms
show a de novo c.421G>A change in the index case. B) Suppression of btg2 leads to head size defects. Dorsal view of
uninjected (UI) control and btg2MO-injected zebraﬁsh embryos at 4 dpf. White arrows show the distancemeasured
from forebrain to hindbrain. Red line shows the protrusion of the pectoral ﬁns in UI controls (for comparison with btg2
morphant). C) Distribution of head sizemeasurements at 4 dpf (Table A.10; white arrows in C), a.u., arbitrary units;
n = 49–79 embryos per injection. D) Suppression of btg2 leads to a decrease of HuC/D levels at 2 dpf. Representative
ventral images of control, btg2morphants (images show unilateral or absence of HuC/D expression), and a rescued
embryo injected with a btg2MOplus human BTG2wtmRNA. E) Percentage of embryos with normal, bilateral HuC/D
protein levels in the anterior forebrain or decreased/unilateral HuC/D protein levels in embryos injected with btg2
MOs alone orMOs plus human BTG2WTor variant mRNAs (p.V141M, index case; p.A126S and p.R145Q, control
alleles). : p < 0:05 (two-tailed t-test comparisons betweenMO-injected and rescued embryos; n = 38–78 embryos
per injection batch).
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HuC/D staining comparable to wt mRNA, providing evidence for assay specificity (Figure 2.4E). As
a third test, we stained whole embryos with a phospho-histone H3 (PH3) antibody that marks pro-
liferating cells. We counted the number of positive cells in a defined anterior region of a minimum
of 10 embryos injected with each cocktail (scored blind). We saw a significant reduction in cell prolif-
eration in the heads of 2 dpf btg2morphants (average of 235 PH3-positive cells/embryo head in mor-
phants vs 387 in controls, p<0.0001); this defect was likewise rescued by co-injection of wt mRNA,
while 141Mmutant rescue was indistinguishable from btg2 tb-MO alone (p = 0.38; Figure 2.5A, B).
Combined, all three assays indicated that BTG2 p.V141M is pathogenic and that haploinsufficiency
of this gene likely contributes to the microcephaly phenotype of the proband.
Despite all our functional and genetic data for p.V141M, this allele was predicted to be benign by
each of Polyphen-2, SIFT, andMutationAssessor. The likely reason is that, with the exception of
primates, most other species with a BTG2 ortholog encodeMet at the orthologous position (Fig-
ure 2.5C). These data suggested that V141 might represent a CPD site in primates that branched
from the ancestral methionine residue. To test this possibility, we searched for BTG2 sites that co-
evolved with 141M.We identified nine such sites (Table A.11), which we mutagenized into the hu-
man construct bearing the 141M-encoding allele. We then injected embryos with btg2 MO;MO+wt
human BTG2mRNA;MO+ 141M-encoding mRNA; or MO+ 141M in ciswith one of the nine can-
didate complementing alleles. Seven of the alleles had no effect on this activity (Table A.11). How-
ever, R80K- or L128V-encoded mRNA on the 141M backbone rescued the number of PH3-positive
cells to wt levels (Figure 2.5B; Figure A.3C); both alleles were benign on their own (Table A.11).
Taken together, our data indicated that 141M is deleterious to protein function in the human back-
ground, but the protection to this residue afforded by either Lys 80 or by Val 128 can explain more
than 90% (54/59) of species encoding 141M (Figure 2.5C).
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B
Figure 2.5: 80K and 128Vmutations rescue the BTG2V141M allele. A) Two day-post-fertilization zebraﬁsh embryos
stained for phospho-histone H3. Human RNA containing the V141Mmutation is unable to rescue the reduction of
proliferation observed upon knockdown of btg2. B) Quantiﬁcation of pH3: human RNAwithmutations V141M and
either R80K or L128V can rescueMO knockdown of endogenous btg2. Error bars represent standard deviation. C)
The 141M allele is ﬁxed in 58/87 species besides primates, examples displayed here. See Table A.11 for raw data.
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2.5 Discussion
The ability to test allele function in a biologically relevant context is improving. Nonetheless, these
methods cannot yet be employed at the genome or population level. To improve the scalability of
detecting CPDs, we used our model of CPD evolution to develop a computational predictor for
distinguishing variants that are unlikely to be CPDs from those that might be CPDs, and to iden-
tify candidate compensations to aid in experimental design (http://genetics.bwh.harvard.
edu/cpd/). Initial testing of this tool intimated high negative predictive values but modest positive
predictive values, likely due to the dearth of known CPDs (see Supplementary note).
These results contrast some previous studies that claim that epistasis is ubiquitous 16,36,124;or that
it is practically nonexistent6,130; or that it is commonly of higher order 31,193. The most likely expla-
nation for this discrepancy is that most such studies have examined different kinds of variation and
different kinds of traits. For example, studies on the evolution of genetic incompatibilities rely on
assumptions of high mutation rate and weak negative selection, assumptions that generally do not
hold for the case of pathogenic missense variation 36,59. The difference with the studies suggesting
higher-order cis-interactions may have to do with the scale of evolutionary time our analyses probes:
the span of hundreds of millions of years of evolution represented by the vertebrate alignment may
not be long enough to reveal higher-order combinations of nonsynonymous SNVs. Indeed, using
neutral SNVs from the HumVar dataset as a control, we estimate the vertebrate alignment has ex-
plored 12% of pairwise interactions between SNVs, compared to 0.6% of three-way interactions be-
tween SNVs. It is possible that higher-order interactions are common, but are not detectable with-
out a deeper alignment.
Finally, in the backdrop of accelerated use of genome editing to model human pathogenic muta-
tions in a variety of model organisms, our data highlight the critical need to not only pair computa-
tional predictions with functional studies, but to also evaluate the effect of human mutations in the
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context of the human sequence.
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Why ask about my birth?
Like the generations of leaves, the lives of mortal men.
Now the wind scatters the old leaves across the earth,
now the living timber bursts with the new buds
and spring comes round again. And so with men:
as one generation comes to life, another dies away.
But about my birth, if you’d like to learn it well,
ﬁrst to last—though many people know it—
here’s my story.
Homer, Iliad book 6 83
3
Parametric rate estimation in proteins
The Bayesian rate estimator score included in the HCM predictor reported in chapter 1
turns out to be a very useful feature. Unlike the other scores developed in that chapter, it is not de-
pendent on the specific genes under study and their biochemical or biophysical properties; it is in
principle applicable to the entire genome. Furthermore, it appears to add information to the un-
modified PolyPhen-2 score despite being ostensibly based on the same information (the multiple
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sequence alignment). If it could be plausibly precomputed or made faster, it would be possible to
include this score in the general-purpose version of PolyPhen. With this in mind, I set out to im-
plement a faster score that incorporates the same parametric model as this Bayesian rate estimator
score.
I investigated several possibilities for this score. One class of rejected estimators attempted to gen-
erate an equilibrium distribution of amino acid frequencies π, the same quantity PolyPhen and
SIFT estimate. Another class allowed for shifting amino acid preferences throughout the tree, at-
tempting to incorporate my model of multisite interactions from chapter 2. Ultimately all of these
models appeared to have too many parameters for the number of sequences we have in our align-
ment. This problemmay be exacerbated by the flatness of the likelihood landscape, as alluded to in
the introduction. It is possible that these models may become tractable once our alignments contain
thousands of vertebrate sequences rather than hundreds. Ultimately the score that worked best was
a simple rate, very similar to the Bayesian rate estimator score reported in chapter 1. It is also fairly
similar to to several existing parametric methods, though those methods use nucleotide sequences
rather than amino acid sequences, a fact which may contribute to performance 33,41,74,154.
The remainder of this chapter is a manuscript that is currently under review for publication. The
cross-validation procedure was designed and implemented by Ivan A. Adzhubey; the remainder of
the text is my work, with advice and support from Professor Sunyaev.
3.1 Background
Estimating the level of selective constraint on a sequence is one of the most common tasks in com-
putational genetics. In addition to being important to the history and dynamics of evolution, se-
lective constraint can be used as a proxy for biological importance or strength of phenotypic ef-
fect4,93,145,170,207. In this context, estimates of selective constraint are often used for such purposes
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as selecting variants that are likely to be causative of rare Mendelian disorders7,34, developing ani-
mal models of diseases62, and identifying possible binding sites for transcription factors79,195, among
others. There are many existing methods designed for these purposes, including complete phyloge-
netic analysis packages that are capable of producing rate estimates, such as PAML 201, MrBayes 161,
PLEX42, and HyPhy 140,155, as well as tools that have estimation of constraint as their primary pur-
pose, like phyloP 154, GERP++41, LRT 33, and fitCons74.
Many phylogenetic analysis programs include estimations of evolutionary rate as part of their
analysis. In particular, it is common for these tools to use a parametric model of evolution with
multiple rate categories or a distribution of rates, with different sites evolving under different levels
of constraint, or, in some cases, under different levels of positive selection. These rate categories are
inferred along with the tree structure, and provide information about the dynamics of evolution
over an entire gene or series of genes. These tools are extremely versatile, supporting a wide variety
of models of evolution and methods of phylogenetic inference. However, for the particular purpose
of rate estimation they are fairly coarse-grained, with one rate category typically containing many
nucleotides or codons, and cannot generally be used to evaluate the level of constraint at a particular
site.
Methods like phyloP, GERP++, LRT, and fitCons are specifically designed to address the prob-
lem of assigning precise levels of constraint to particular sites. These methods vary in their specific
models and implementations, but they generally use a similar approach. Given a multiple sequence
alignment and a precomputed tree describing the relationships between the sequences in the align-
ment, these methods use parametric models of evolution to estimate the likelihood that a particular
site is evolving under constraint. Each of these methods uses a slightly different statistical formula-
tion of the problem and computes its final score differently, but each effectively uses a likelihood
model to estimate the rate of evolution, and then scores whether that rate is consistent with neutral
evolution or implies constraint. These methods are typically used to detect patterns of conservation
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in sequences, including detection of blocks of conserved sequence. Some methods, such as fitCons,
also incorporate other sources of information to distinguish functional regions, including patterns
of DNAse hypersensitivity and histone modifications.
These methods typically use nucleotide sequences only, and therefore may fail to capture some
biochemical information about the protein sequence. Those that do use amino acid sequences still
explicitly model substitutions at the nucleotide level, using a codon model. The main reason for this
is the tractability of the model: where a nucleotide-level model of evolution must supply or infer
a 4  4 substitution matrix (one row and column for each of the four standard nucleotides), or
12 independent rate parameters, a full amino acid model requires a 20  20 matrix (one row and
column for each of the twenty standard amino acids), or 380 independent rate parameters. The
extremely high dimensionality of the amino acid model makes inference of the model parameters
unfeasible for the typical use cases of these tools, which involve a single site observed in fewer than
100 taxa.
While a full parametric treatment of an amino acid substitution model might not be feasible, it is
in principle possible to estimate certain relevant features of such a model. One useful feature is the
stationary distribution of amino acid frequencies at a particular site, which in principle represents
the profile of amino acids tolerated at that site 101. Several methods exist to estimate this quantity
from a multiple sequence alignment, including SIFT 142 and PSIC 171, which may be more familiar as
a component of ensemble predictors of variant effect such as PolyPhen-2 2 or SNAP 18. These meth-
ods forego the parametric model, instead using the observed distribution of amino acids produced
by evolution within a given phylogeny to estimate the stationary distribution of amino acids. They
consistently outperform parametric rate estimation methods like phyloP and GERP++ at the task of
separating neutral from deleterious mutations 52,108, demonstrating that the stationary distribution
of amino acids contains useful information about evolutionary constraint that is not available to
parametric models.
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Here, we present a new parametric method for estimating evolutionary rate, BARE (Bayesian
Amino-Acid Rate Estimator). Unlike existing methods, BARE uses a pure amino acid substitution
model. We use an estimate of the stationary distribution of amino acids produced by PSIC to con-
strain the model, allowing the parameters to be efficiently inferred at a single site with fewer than
100 taxa. This method outperforms existing parametric methods, as well as providing additional
information apparently not captured by the raw PSIC profile.
3.2 Methods
3.2.1 Model
Our method is based on a standard parametric model of protein evolution from the generalized
time-reversible (GTR) class of models, which models evolution as a branchingMarkov process with
a constant transition rate matrix Q92. The rate matrix Q represents the instantaneous rate of tran-
sition between states: Qij for i 6= j represents the rate of transition from state i to state j, with the
diagonal elements Qii given by the requirement that the columns of the matrix sum to zero, i.e. that
X
j
Qji = 0 (3.1)
The rate matrix Q is used to compute the transition probability matrix P(t), where Pij(t) represents
the probability of observing state j at time t0 + t conditional on observing state i at time t0. P(t) is
given by
P(t) = eQt (3.2)
where eQt represents the matrix exponential.
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The elements of the transition rate matrix Qij are given by
Qij =
8><>: μθijπj if i 6= j Pk 6=i Qki if i = j (3.3)
where π is the vector of stationary amino acid frequencies, θ is a rate matrix representing the ex-
changeability of amino acid states independent of their frequencies, and μ is a scale factor applied to
the entire matrix. This formulation guarantees that the stationary distribution of amino acids π and
the rate matrix Q obey the stationarity criterion
π  Q = 0 (3.4)
In other words, the net transition rate is zero when the distribution of amino acids matches the sta-
tionary distribution π.
This separation of the stationary state frequencies π from the exchangeability parameters θ
makes it straightforward to constrain this model by choosing a fixed exchangeability matrix θ, al-
lowing only the vector π and the scale factor μ to vary freely 20,92. This produces a model with 20
free parameters, representing 19 independent stationary-state amino acid frequencies πi and the
scale factor μ. The 20th amino acid frequency is given by the normalization requirement,
X
i
πi = 1 (3.5)
3.2.2 Priors and Constraints
We used a θmatrix derived from the empirical substitution matrix of Jones, Taylor, and Thorn-
ton98. We fix π for each individual site using PSIC 171, which estimates π based on a multiple se-
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quence alignment of amino acid sequences. This is the essential novelty of our method, and it allows
us to evaluate rapidly a parametric model for each amino acid site independently using the full al-
phabet of amino acids. Fixing θ and π leaves a single free parameter: the scale parameter μ, which
represents the overall rate of evolution at the site. We applied this model to the phylogenetic tree
provided by the MultiZ orthologous alignments of 100 vertebrate sequences, available on the UCSC
genome browser 103. We populated the tree with amino acid identities from a single site of the align-
ment, and computed a maximum a posteriori estimate of the single paramter μ. As a prior for μ, we
used an uninformative gamma prior with parameters α = β = 1.
3.2.3 Validation
There is no direct way to test the predictions of the method, because there are no known “true”
values for the rate of evolution. One commonly used proxy is the task of separating known be-
nign variants from known pathogenic variants, as sites containing pathogenic variation are more
likely to be under evolutionary constraint. This task is also important for several of the most com-
mon and important use cases of estimates of variant effect, which include prediction of variant ef-
fect and prioritization of variants. We tested our method using the HumVar dataset of variant an-
notations 22, derived from amino acid variant annotations listed in the UniProt database (http:
//www.uniprot.org/docs/humsavar). We compared the performance to phyloP, GERP++,
and LRT scores extracted from the dbNSFP database of variant annotations 123; PSIC scores rep-
resenting the log likelihood of the wild-type amino acid (“Score1”) and the log likelihood ratio of
the wild-type and variant amino acids (“dScore”); and the full ensemble of 11 features used by the
current version of PolyPhen-2 (Figure 3.1). All scores were used as features of Naive Bayes classifiers
with discretization, implemented inWeka (http://www.cs.waikato.ac.nz/ml/weka/), and
trained and scored in 5-fold cross-validation, stratified so that each gene was only included in a single
fold.
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3.2.4 Availability
The method is implemented in C++ using the Bio++ library (http://biopp.univ-montp2.
fr/), and is freely available under the GPL license at http://bwh.harvard.edu/bare.
3.3 Discussion
3.3.1 Performance
As a proxy for the accuracy of our method at predicting the level of evolutionary constraint, we mea-
sured its ability to distinguish known neutral variants from those known to cause disease in humans
(Figure 3.1). Using our cross-validation procedure (see section 3.2.3), we find that our method out-
performs existing parametric methods at this task. Our method’s performance was comparable to
but worse than that of PSIC, a non-parametric method that does incorporate amino acid identities.
However, when combined with PSIC in an ensemble classifier, our method improves its perfor-
mance noticeably, and to a larger degree than other tree-aware methods.
3.3.2 Precomputed Dataset
In our C++ implementation, the method is fast enough that we can precompute the rate score for
all coding positions in all known transcripts of human protein-coding genes. We used this dataset to
compare our rate score to precomputed scores from other methods stored in the dbNSFP database,
excluding fourfold synonymous sites 123. Our score shows reasonably good but not perfect correla-
tion with other scores including phyloP (Spearman rho = -0.65), GERP++ (Spearman rho = -0.51),
and LRT (Spearman rho = 0.68). Most discrepancies between the different methods are probably
accounted for by the fact that BARE is aware of the chemical properties of different amino acids,
while the other methods are not. Partitioning the dataset based on the amino acid type found at
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each position confirms the importance of amino acid type: both BARE and the other methods re-
flect differences in conservation patterns between different amino acid types, as expected98, but
BARE shows remarkably different patterns from the other methods (Figure 3.2A–B). Different
amino acid types also show a wide range of correlations, with Spearman rho values for specific types
of amino acids ranging from approximately 0.5 to 0.8 (Figure 3.2C). Measuring prediction perfor-
mance on this stratified dataset (Table 3.1) indicates that, although BARE has better performance
overall, BARE does not necessarily have the advantage in all cases where BARE and phyloP disagree.
For example, amino acid aware methods appear to perform consistently better in amino acids with
charged side chains (aspartic acid, glutamic acid, arginine, and lysine), while nucleotide-only meth-
ods in amino acids with aromatic rings (histidine, phenylalanine, tryptophan, and tyrosine).
3.4 Conclusion
We have presented BARE, a new tool to score the evolutionary constraint on protein coding po-
sitions. Mathematically, this method is similar to the computations performed by the phyloP 154,
GERP++41, and LRT 33 methods to compute a “neutral rate” of evolution at each site, with the
difference that BARE explicitly accounts for biochemical properties of amino acid sequences and
is thus potentially more informative about coding sequences. Explicitly modeling amino acid se-
quences in this way has a significant impact on this rate calculation, especially for amino acids with
important biochemical properties like aromatic rings or charged side chains.
Without a reliable way of measuring the “true” rate, it is impossible to say which estimator is
more accurate, but we argue that modeling amino acid sequences is essential to creating an accurate
map of constraint in protein-coding sequences. One indication that the BARE estimator performs
well is that it more accurately separates pathogenic missense variants from neutral missense variants.
65
False positive rate
Tr
u
e
 p
os
itiv
e
 r
a
te
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
AUC :
0.682 ± 0.006     GERP++
0.759 ± 0.005     phyloP
0.806 ± 0.002     PSIC
0.779 ± 0.005     BaRE
0.816 ± 0.001     PSIC + BaRE
0.831 ± 0.002     PolyPhen−2
0.756                  LRT
Figure 3.1: ROC analysis for BARE comparedwith other methods. “GERP++,” “phyloP,” and “BARE” represent single-
feature Naive Bayes classiﬁers. “PSIC” represents a two-feature Naive Bayes classiﬁer, using wild-type PSIC score
(Score1) and difference in PSIC scores (dScore). “PSIC + BARE” represents a three-feature Naive Bayes classiﬁer
combining the two PSIC scores and BARE. “PolyPhen-2” represents the standard 11 features of PolyPhen-2, i.e. the
current complete PolyPhen-2 classiﬁer. LRT is a raw score taken from the dbNSFP database. All classiﬁers except LRT
are averages from 5-fold cross-validation, with standard error ranges.
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Table 3.1: Classiﬁcation accuracy of Naive Bayes classiﬁers (testing-on-training) for different amino acid types. Amino
acid awaremethods and nucleotide-basedmethods show different proﬁles of accuracies depending on amino acid
types, demonstrating that an amino acid level substitutionmodel doesmake a signiﬁcant difference in these rate esti-
mates. Valuesmarkedwith  are statistically signiﬁcant departures from the overall value (20-sample test for equality
of proportions without continuity correction, with Bonferroni multiple test correction).
Amino Acid GERP++ phyloP PSIC BARE PSIC + BARE
Overall 0.66 0.70 0.74 0.73 0.75
Ala 0.67 0.74 0.77 0.75 0.78
Cys 0.77 0.77 0.82 0.81 0.82
Asp 0.63 0.68 0.73 0.72 0.74
Glu 0.59 0.64 0.65 0.68 0.68
Phe 0.64 0.70 0.69 0.67 0.69
Gly 0.80 0.84 0.84 0.83 0.85
His 0.65 0.69 0.72 0.72 0.74
Ile 0.62 0.67 0.73 0.63 0.71
Lys 0.53 0.62 0.66 0.65 0.66
Leu 0.67 0.69 0.68 0.64 0.68
Met 0.65 0.72 0.66 0.72 0.70
Asn 0.59 0.65 0.76 0.74 0.77
Pro 0.68 0.76 0.74 0.76 0.76
Gln 0.62 0.70 0.71 0.71 0.74
Arg 0.69 0.65 0.76 0.76 0.76
Ser 0.61 0.68 0.73 0.70 0.74
Thr 0.64 0.72 0.76 0.73 0.76
Val 0.62 0.67 0.74 0.67 0.73
Trp 0.78 0.80 0.80 0.79 0.80
Tyr 0.67 0.68 0.72 0.69 0.72
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However, while this task represents an important part of the use of these tools7,34, it is not necessar-
ily directly related to the task of estimating evolutionary constraint. It is also undeniably true that
BARE cannot detect conserved noncoding elements, which is one common use of tools like phyloP
and GERP++. In general, we do not consider BARE to be a strict improvement on these tools, but
rather an additional resource to be used together with them.
We have precomputed the BARE score for every protein-coding position in the human genome,
as indexed by the UCSC genome browser database (http://genome.ucsc.edu/). These values
are available at http://genetics.bwh.harvard.edu/bare, in the form of a genome browser
track that can be displayed on the UCSC genome browser, a SQLite3 database, and a tab-delimited
text file. We hope that making this resource available will provide the community with a new source
of information about evolutionary constraint and the selective landscape experienced by protein-
coding sequences.
In addition to these precomputed scores, we have released the source code to compile and run
BARE as a standalone tool. The program takes as an argument a phylogenetic tree, an alignment of
amino acid sequences, and a position in amino acid coordinates. We have exclusively used the UCSC
MultiZ whole-genome orthologous alignments of 100 vertebrate species, along with its correspond-
ing species tree; however, in principle any custom alignment or tree is accepted. Additionally, since
it is possible to use a different tree for each position, BARE is in principle compatible with a wide
variety of different tree models, including models involving widespread incomplete lineage sorting
and horizontal gene transfer43,202, as well as relaxed and local molecular clocks 19,46,174. The trees are
accepted in the standard Newick format, so a wide variety of external programs can be used to create
these input trees. Similarly, the raw rate estimate produced by BARE can also be further processed
to generate a variety of other scores that measure constraint, such as phyloP’s constraint p-value or
GERP++’s “rejected substitutions” score. In the case of GERP++ in particular, the BARE score
can be used as a drop-in replacement for the native “neutral rate” score. This makes BARE a very
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versatile tool with a wide variety of applications to computational genetics research.
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Polar Charged Aliphatic Aromatic
(a)
Polar Charged Aliphatic Aromatic
(b)
Polar Charged Aliphatic Aromatic
(c)
Figure 3.2: Comparison of conservation scores for whole-exome datasets of BARE and phyloP scores (phyloP is used
as a representative of nucleotide-level tree-based scores). Panels A and B showmedian scores fromBARE (a) and
phyloP (b). Higher values represent greater levels of conservation. Panel C shows correlation (Spearman rho) between
BARE and phyloP. Dashed black line shows values for the complete unpartitioned dataset.
70
4
Conclusion
The field of variant effect prediction is in a somewhat confusing state. The general perception is
that existing tools are immature and not to be trusted71,153,176,205, leading to the release of new tools
year after year25,34,101,108,144. Each new tool claims significant improvements over its predecessors, but
independent analyses indicate that all methods have roughly comparable performance, with typi-
cal accuracy hovering around 80%72,183. In fact, despite the appearance of immaturity, these tools
are extremely mature and rest on well-developed methodologies. The easy ways to improve perfor-
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mance by incorporating new scores and newmachine learning techniques have generally already
been found; the remaining improvements are difficult.
In this dissertation, I have presented three of my attempts at these difficult improvements. In the
first chapter, I improved the method’s applicability to a specific clinical problem. In the second, I
addressed the method’s handling of epistasis. In the third, I incorporated a parametric model that
explicitly models the tree structure of evolution. In all three cases, the results are not magical up-
grades that dramatically improve performance. In chapter 1, the performance improvement was
fairly dramatic, but this improvement required application of significant biological and biochemical
insights. The most effective new score, the structure pair score, is actually impossible to compute
for the vast majority of genes; the next most effective, the coiled-coil score, has no detectable pre-
dictive power when applied to the genome-wide HumVar dataset. The other major contributors to
accuracy—manual curation of alignments and inclusion of the “no call” classification—are unique
to the specific application and are not necessarily feasible to apply to a general-purpose or genome-
wide predictor. The results from chapter 2 are arguably even more discouraging: my best attempt
at predicting CPDs is utterly incapable of making a prediction without the aid of an in vivomodel.
Only chapter 3 has any kind of wide applicability to automated methods, and its performance im-
provement, though significant, is extremely modest. All in all, none of these advances are likely to
be incorporated into the next version of PolyPhen. Instead, what makes the most difference in the
performance of prediction methods are the continuous updating of databases of sequences and vari-
ants, not any theoretically interesting advance.
This should not necessarily be discouraging. Advances of the magnitude reported in chapter 1
may require specific biological knowledge and consulation with medical experts, but there is a great
deal of such knowledge and expertise in the field. Furthermore, with the development of text min-
ing algorithms and ontologies of biological models and phenotypes 107,121, this knowledge becomes
easier and easier to access. Likewise, the method reported in chapter 2 requires in vivo experimenta-
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tion to complement computational predictions, but these experiments continue to become faster
and cheaper. Prioritizing variants to the point where the experiment can be followed up by in vivo
methods is becoming a less and less onerous task. This kind of biological knowledge and experi-
mental validation becomes more and more important as we move towards predicting more specific
phenotypes and more complex genetic architectures, both of which are especially vital to the clin-
ical use of these predictors. Additionally, as the amount of available data continues to grow, even
complex and biologically specific problems like these become more and more tractable to automated
methods.
In general, in order for these prediction methods to remain useful into the era of widespread
clinical and population-level sequencing, they must become platforms for a wide range of more
specific biological analyses, rather than attempting to be better at the general task of predicting the
effects of variants. We should be skeptical of advances that claim to instantly improve performance
by incorporating more data or new algorithms, and instead look for ways of extending and refining
these already well-developed methods.
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Supplementary Material to Chapter 2
The bulk of chapter 2 is a manuscript currently in press atNature99. The material in this appendix
will be available as an online supplement to that manuscript once it is published.
Supplementary Note: Additional characterization of CPDs
To characterize further our detected CPDs, we performed enrichment analysis on functional an-
notations and modes of inheritance. We performed Gene Ontology (GO) term enrichment analy-
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sis using the AmiGO term enrichment tool (http://amigo1.geneontology.org/cgi-bin/
amigo/term_enrichment), using the default thresholds of maximum p-value 0.01 (before mul-
tiple test correction) and minimum number of gene products 2. No significant term enrichments
were found. We also performed annotation cluster enrichment analysis using the Database for An-
notation, Visualization and Integrated Discovery (DAVID) functional annotation clustering tool90.
This analysis showed modest enrichment for terms representing secreted extracellular compounds,
integral membrane proteins, ion channels, and vacuoles. Other enrichments span a broad range of
biological systems and processes, including blood clotting, blood lipid regulation, perception and
cognition, hormone response, and embryonic development (Table S3).
Next, we performed enrichment analysis on modes of inheritance. Modes of inheritance were
downloaded fromOrphanet (http://www.orpha.net/), which labels diseases with inheritance
categories including Autosomal Dominant, Autosomal Recessive, XLinked, Sporadic, andMulti-
genic/Multifactorial. In both the ClinVar and HumVar datasets, enrichment analysis found small
but highly significant depletion for Autosomal Dominant, Autosomal Recessive, and X-Linked
modes of inheritance, and significant enrichment for Multigenic/Multifactorial inheritance (Ta-
ble S4). This is in keeping with our expectations, since diseases with multigenic and multifactorial
modes of inheritance inherently involve multiple sites and thus should be more readily subject to
compensation.
Finally, we searched dbSNP for candidate CPDs whose presence in the alignment may be ex-
plained by the variant being polymorphic in the other species. We found a total of 10 candidate
CPDs that are present in dbSNP for another species (Table S5). Out of these, all but one were present
in multiple species other than the one with a known polymorphism, suggesting that in general there
are very few cases where a variant is found in the alignment solely because it is polymorphic. How-
ever, we cannot fully address the intersection of polymorphism and CPDs without more polymor-
phism data from a wider range of species.
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These analyses complement previous studies that have examined the structural and chemical
properties of CPDs, finding that CPDs are likely to be structurally destabilizing rather than impair-
ing a specific biochemical function, and that they are likely to have milder effects on folding stability
than other pathogenic SNVs 8,55.
Supplementary Note: CPD predictor usage
Based on our experience with the identification of a novel human disease gene containing a CPD, we
suggest a Bayesian approach to CPD identification, supported by our probabilistic predictor. The
BTG2V141M allele, identified as pathogenic in vivo but predicted as benign by multiple computa-
tional tools, should be considered initially an ambiguous case due to conflicting evidence. Our CPD
predictor reports that it is unlikely but possible that this variant is a CPD, with probability 1.6%.
This value represents the Bayesian posterior based solely on the alignment. However, by presenting
human genetic evidence, demonstrating experimentally that the V141M allele is functional, and lo-
cating the compensating alleles that account for its presence in almost all orthologous sequences, we
are able to plausibly claim that this variant falls in the 1.6% of variants seen in similar alignments that
are CPDs, and dismiss the computational prediction as a false negative. If, on the other hand, the
CPD predictor had reported a probability well below 1%, we might remain unconvinced even in the
face of our genetic and functional evidence; meanwhile, if it had reported a probability well above
5%, the functional and genetic evidence might have been sufficient without identifying the compen-
sating alleles. In our dataset, approximately 1,800 benign variants and 60 pathogenic variants are
assigned a probability below 1%, while approximately 5,600 benign variants and 1,800 pathogenic
variants are assigned a probability above 5%. The web interface outputs three distinct messages that
repeat these recommendations.
Predicting specific compensating sites, though also desirable, is not feasible based on our current
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knowledge. There are several theoretical models to explain the biochemical basis of compensatory
events. These include reconstitution of destabilized tertiary structure, restoration of protein stabil-
ity, and improvement of protein-protein interaction capabilities within a complex 8,47. However, we
do not know the biochemical basis of the compensatory events discovered here; for each of BBS4,
RPGRIP1L, and BTG2, there was little a priori evidence for any of these interactions. The validated
interactions can be long-range in terms of primary sequence, with one spanning more than 700
residues (Figure S3); none of the three proteins tested have known 3D structures; and none of these
interactions suggest obvious biochemical mechanisms for rescue, such as balancing, electrostatic
charge, or replacement of phosphorylation sites. It would be challenging for any computational
method to account for these interactions and to make the correct prediction. Until more validated
examples are collected, and/or until we have more biochemical information about those examples
we have collected, predicting specific interactions in a principled way is not feasible. Instead, we
have made available the method we used to design the experiments we reported here. This method
simply treats any substitution that co-occurs with the candidate CPD as a candidate compensation,
prioritizing sites that are substituted in multiple different species. These candidate lists may require
fairly high-throughput experimental systems to test them. A more principled approach would not
have this limitation.
Both the CPD prediction tool and the candidate compensation tool are available online at http:
//genetics.bwh.harvard.edu/cpd/. These tools should make it easier to interpret the output
of computational tools like PolyPhen and SIFT, and to design experiments like those we report
here. We expect future studies to develop more accurate predictors, possibly incorporating known
functional and structural features of CPDs 8,55 and/or attempting to predict compensation sites in a
principled way.
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Supplementary Note: Manual evaluation of false-positive pathogenic alle-
les
To evaluate the false-positive annotation of variants as pathogenic in the unfiltered HumVar dataset,
we selected 100 alleles randomly from the HumVar pathogenic alleles list, and another 100 random
alleles from the HumVar compensated alleles list (a subset of the HumVar pathogenic alleles that are
also found in other species). We inspected the evidence supporting the alleles manually, discarding
any that were obvious false positives based on the following criteria:
a. in vitro or in vivo functional studies showed benign or only minor effects not significantly
different from wild type;
b. no evidence of pathogenicity;
c. common polymorphisms (present in homozygosity in healthy controls, and/or minor allele
frequency greater than 5%); or
d. incorrect annotation.
We found that 5/100 alleles in the HumVar pathogenic list and 6/100 alleles in the HumVar compen-
sated list were annotated falsely as pathogenic.
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Table A.1: Number of variants from all datasets shared between alignment strategies.
MultiZ
Unfiltered
MultiZ
Mammals
MultiZ
only EPO
sequences
EPO MultiZ
High Qual-
ity
MultiZ >1
Species
MultiZ
Unfiltered
16984 13766 11561 10135 13973 13174
MultiZ
Mammals
13766 13766 11561 9698 11220 11681
MultiZ only
EPO
sequences
11561 11561 11561 9096 9360 10519
EPO 10135 9698 9096 11236 8339 9072
MultiZ
High
Quality
13973 11220 9360 8339 13973 10786
MultiZ>1
Species
13174 11681 10519 9072 10786 13174
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Table A.2: Pathogenic human alleles present in multiple species.
(a) Present in both ClinVar andHumVar 2 species
Gene Allele Human Disease Species EVS Inheritance Onset Reference Comment
SCN5A
Val1951Met Atrial fibrillation 59 absent dominant adolescence 40
Arg680His Sudden unexplained
death (SUD), Sudden
infant death syndrome
(SIDS)
43 absent dominant young adult 29, 189
Ala997Ser Long QT Syndrome 10 absent unknown infancy 1
ATRX Leu409Ser X-linked mental retarda-
tion
24 absent X-linked childhood 196
AQP2
Leu22Val Congenital nephrogenic
diabetes insipidus (NDI)
17 absent recessive congenital 21
Ser216Pro Congenital nephrogenic
diabetes insipidus
2 absent recessive congenital 44, 45, 186
ZNF81 Ser179Asn X-linked mental retarda-
tion
9 absent X-linked childhood 109
CFTR Ile1234Val Cystic fibrosis 8 absent recessive childhood 137
TNNI3 Asn185Lys Dilated cardiomyopathy 8 absent dominant childhood 23
AMHR2 Arg406Gln Persistent Mullerian duct
syndrome
6 absent recessive congenital 12, 132
OTC Thr125Met Ornithine carbamoyl-
transferase deficiency
5 TT=0/TC=1/CC=4058/C=2443 X-linked congenital 66, 173 cis-
compensation
with 135T
TRPV4 Arg269His Charcot-Marie-Tooth
disease
5 absent dominant childhood 117
FGFR3 Asp513Asn Lacrimo-auriculo-
dento-digital (LADD)
syndrome
3 absent dominant congenital 160
FIG4 Ile41Thr Charcot-Marie-Tooth
disorder, type 4J
2 CC=0/CT=15/TT=6487 recessive childhood 32, 119
PDE8B His305Pro Bilateral adrenocortical
hyperplasia/Cushing
syndrome
2 absent dominant childhood 85, 86
AIRE Leu29Pro autoimmune polyen-
docrinopathy (APE)-
candidiasis (C)-
ectodermal dystrophy
(ED), APECED
2 absent recessive infancy 78, 110
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Table A.2: (continued)
(b) Present in both ClinVar andHumVar 1 species
Gene Allele Human Disease Species EVS Inheritance Onset Reference Comment
LHX4 Arg84Cys Growth hormone defi-
ciency
1 absent recessive childhood 151
PROP1 Arg99Gln Combined pituitary
hormone deficiency
(CPHD)
1 absent recessive adolescence 187
POF1B Arg329Gln Premature ovarian failure
(POF)
1 TT=0/TC=35/T=8/ CC=4025/C=2435 X-linked adolescence 116, 149
GCM2 Gly63Ser Familial isolated hy-
poparathyroidism
1 TT=0/TC=1/CC=6502 recessive childhood 127, 182
NOG Tyr222Cys Proximal symphalangism
and multiple synostoses
syndrome
1 absent dominant congenital 50, 70
SI Gln117Arg Congenital sucrase-
isomaltase deficiency
(CSID)
1 absent unknown congenital 169
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Table A.2: (continued)
(c) Present in ClinVar 3 species
Gene Allele Human Disease Species EVS Inheritance Onset Reference Comment
PRSS1
Asn29Thr Hereditary chronic
pancreatitis
68 absent dominant childhood 152, 166
Arg122His Hereditary chronic
pancreatitis
5 absent dominant childhood 28, 177, 194, 197
CD96 Thr280Met C Syndrome/Opitz
Trigonocephaly
27 absent de novo infancy 102
KCNA5 Ala576Val Atrial fibrillation 25 absent dominant adolescence 200
LTBP2 Val1177Met Weill-Marchesani syn-
drome
9 absent recessive congenital 77
NR5A1 Gly212Ser Spermatogenic failure 9 TT=0/TC=1/CC=6280 de novo adolescence 9
KISS1R Arg386Pro Central precocious pu-
berty
6 absent de novo adolescence 14, 178
HSD17B3 Ala203Val Testosterone 17-beta-
dehydrogenase defi-
ciency/Male pseudo-
hermaphroditism
6 absent recessive congenital 61
CYP21A2
Pro30Leu 21-hydroxylase deficiency 6 absent recessive congenital 131, 147, 168, 185
Pro105Leu Congenital adrenal
hyperplasia (CAH)
4 absent recessive congenital 146
ABCB6 Ala57Thr Microphthalmia, iso-
lated, with coloboma
5 absent dominant congenital 191
ELANE Val98Leu Severe congenital and
cyclic neutropenia
5 absent recessive congenital 65, 157, 163 called V69L
TBC1D24 Phe251Leu Familial infantile my-
oclonic epilepsy
3 absent recessive childhood 35
NEFL Pro22Ser Autosomal dominant
Charcot-Marie-Tooth
disease
3 absent dominant childhood 54, 63, 164
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Table A.2: (continued)
(d) Present in HumVar 3 species
Gene Allele Human Disease Species EVS Inheritance Onset Reference Comment
ATP7B Met1169Val Wilson disease 74 absent recessive childhood 88
GH1 Ser134Arg Dwarfism/short stature 59 absent dominant childhood 134 called S108R
GLA Arg356Gln Fabry disease 11 absent X-linked childhood 94, 162
COLQ Arg410Gln End-plate acetyl-
cholinesterase deficiency
8 absent recessive congenital 148
SUMF1 Leu20Phe Multiple sulfatase defi-
ciency
7 absent unknown childhood 37
MUTYH Arg182Trp Familial adenomatous
polyposis
5 absent recessive childhood 136
NODAL Glu203Lys Autosomal visceral het-
erotaxy/ cardiovascular
malformations
5 absent sporadic congenital 135
KAL1 Phe517Leu Hypogonadotropic
hypogonadism
3 absent X-linked childhood 24, 64, 89
NAGLU Ala246Pro Mucopolysaccharidosis 3B 3 absent recessive childhood 10
FOXE3 Gly49Ala Anophthalmia and
microphthalmia
3 absent dominant congenital 96
F8 His1066Tyr Hemophilia A 3 absent X-linked congenital 76, 150 called H1047Y
(e) Present in ClinVar 1–2 species
Gene Allele Human Disease Species EVS Inheritance Onset Reference Comment
HSD11B2 Asp223Asn Apparent Mineralocorti-
coid Excess (AME)
2 absent recessive congenital 26
CD79B Gly138Ser Immunodeficiency 2 absent recessive childhood 51 called G137S
TRPA1 Asn855Ser Autosomal-dominant
pain syndrome (FEPS)
2 absent dominant congenital 114
(f) Present in HumVar 1–2 species
Gene Allele Human Disease Species EVS Inheritance Onset Reference Comment
ITGA2B Pro943Leu Type II Glanzmann
thrombasthenia
2 absent recessive childhood 97 called P912L
SLC2A9 Arg171Cys Renal hypouricemia type
2
2 absent recessive childhood 48
ARSA Ala18Asp Metachromatic leukodys-
trophy (infantile form)
2 absent recessive infancy 73
SLC7A9 Ala70Val non-Type I cystinuria 2 absent recessive childhood 58
ARSB Cys192Arg Type VI mucopolysaccha-
ridosis
1 absent recessive childhood 95, 199
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Table A.3: Top 50 annotation clusters identiﬁed byDAVID analysis
Cluster number Representative annotation Enrichment score
1 secreted 15.3
2 blood coagulation 13.1
3 visual perception 12.8
4 blood circulation 11.8
5 response to hormone stimulus 10.2
6 chordate embryonic development 10.2
7 lytic vacuole 9.21
8 protein homodimerization activity 9.05
9 ion homeostasis 6.00
10 response to nutrient levels 8.61
11 muscle contraction 7.83
12 steroid biosynthetic process 7.54
13 kidney development 6.88
14 membrane fraction 6.87
15 limb development 6.11
16 intrinsic to plasma membrane 5.92
17 heart development 5.87
18 cellular amino acid derivative metabolic process 5.87
19 neurodegeneration 5.47
20 eye development 5.31
21 sex differentiation 5.29
22 EGF calcium-binding 5.18
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Table A.3 (continued)
Cluster number Representative annotation Enrichment score
23 oxidation reduction 5.14
24 vesicle 5.00
25 neural tube development 4.99
26 forebrain development 4.98
27 vasculature development 4.89
28 structural constituent of cytoskeleton 4.85
29 glycation 4.83
30 pigment biosynthetic process 4.58
31 acute inflammatory response 4.57
32 ion transport 4.25
33 respiratory system development 4.15
34 response to carbohydrate stimulus 4.12
35 platelet alpha granule 4.06
36 cell adhesion 3.90
37 collagen 3.88
38 vacuole organization 3.78
39 regulation of protein modification process 3.76
40 cilium 3.72
41 metalloprotein 3.71
42 bone development 3.61
43 transmission of nerve impulse 3.58
44 regulation of neurological system process 3.54
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Table A.3 (continued)
Cluster number Representative annotation Enrichment score
45 steroid biosynthesis 3.48
46 endoplasmic reticulum 3.46
47 folate biosynthesis 3.41
48 regulation of blood vessel size 3.41
49 cholesterol metabolic process 3.41
50 sulfatase 3.38
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Table A.4: Mode of inheritance enrichment analysis.
ClinVar ClinVar Depletion HumVar HumVar Depletion
Pathogenic CPDs p-value Pathogenic CPDs p-value
Autosomal Dominant 2713 252 0.037 4359 432 1:07 10 6
Autosomal Recessive 2773 240 0.00068 5945 633 0.00011
X-Linked 586 35 0.00015 2463 138 1:35 10 29
Sporadic 96 13 0.895 227 16 0.011
Multigenic/Multifactorial 40 9 0.9945 43 11 0.9964
87
Table A.5: Candidate CPD sites with known polymorphisms in other species.
Species rsID Human Variant Species in alignment
Mouse rs8249104 DMBT1:p.Asn546Ser 38
Mouse rs229011447 HFE:p.Gln127His 8
Mouse rs258538416 ABCB4:p.Ile764Leu 9
Mouse rs222883690 USH2A:p.Arg2354His 32
Pig rs325593396 MEFV:p.Phe479Leu 57
Pig rs336797577 PKHD1:p.Tyr2661His 13
Sheep rs406745685 EYS:p.Leu2189Pro 4
Sheep rs160536391 JAG1:p.Ser913Arg 1
Dog rs22977833 HBB:p.Val12Ile 37
Chicken rs314119972 TNFRSF13B:p.Ala181Gly 4
Table A.6: Signiﬁcance of differences between pathogenic and benign distributions for HumVar and ClinVar and vari-
ous alignment strategies (Kolmogorov-Smirnof 2-sample test).
HumVar ClinVar
MultiZ Unfiltered 5:5 10 173 2:0 10 42
MultiZMammals 1:6 10 68 7:0 10 17
EPO 3:1 10 124 3:0 10 19
MultiZ Quality Filtered 2:0 10 153 3:0 10 14
MultiZ >1 Sequences 3:3 10 82 2:4 10 17
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Table A.7: Signiﬁcance of differences between pathogenic variant distributions forMultiZ alignment (mammals only)
(Kolmogorov-Smirnof 2-sample test).
HumVar ClinVar HumVar +
ClinVar
HumVar
+ ClinVar
excluding
ESP
HumVar 0.46 0.77 0.52
ClinVar 0.46 0.42 0.30
HumVar +
ClinVar
0.77 0.42 1.00
HumVar
+ ClinVar
excluding
ESP
0.52 0.30 1.00
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Table A.8: Fitted parameters for models.  indicates value ﬁxed by themodel, not ﬁtted independently. Models are
described in themethods section of themain text. Values aremaximum likelihood estimates; error ranges are standard
errors of the likelihood distribution. Intersected datasets (HumVar+ClinVar, HumVar+ClinVar+ESP) use HumVar
annotations for neutral variants. Time is measured in sequence distance (1-sequence identity).
model variant alignment mean time
to fix neutral
variants
mean time
to fix CPDs
mean time
to fix com-
pensations
number
of com-
pensatory
sites
Model 1 HumVar MultiZ 0:17 0:001 0:11 0:003 0:110:003 1:4 0:07
mammals 0:14 0:001 0:075 
0:003
0:075 
0:003
1:5 0:08
EPO 0:14 0:001 0:14 0:006 0:14 
0:006
1:7 0:06
quality 0:16 0:002 0:11 0:004 0:110:004 1:4 0:07
# hits 0:14 0:001 0:092 
0:004
0:092 
0:004
1:4 0:09
ClinVar MultiZ 0:16 0:005 0:12 0:006 0:12 
0:006
1:2 0:1
mammals 0:12 0:005 0:083 
0:006
0:083 
0:006
1:2 0:1
EPO 0:13 0:006 0:17 0:01 0:17 0:01 1:4 0:08
quality 0:14 0:006 0:12 0:007 0:12 
0:007
1:2 0:1
# hits 0:13 0:005 0:10 0:007 0:10 
0:007
1:1 0:1
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Table A.8 (continued)
model variant alignment mean time
to fix neutral
variants
mean time
to fix CPDs
mean time
to fix com-
pensations
number
of com-
pensatory
sites
HumVar
/ ClinVar
MultiZ 0:17 0:001 0:11 0:009 0:110:009 1:5 0:2
mammals 0:14 0:001 0:083 
0:009
0:083 
0:009
1:4 0:2
EPO 0:14 0:001 0:18 0:05 0:18 0:05 0:63 0:2
quality 0:16 0:002 0:11 0:009 0:110:009 1:5 0:2
# hits 0:14 0:001 0:10 0:01 0:10 0:01 1:2 0:3
HumVar
/ ClinVar
excluding
ESP
MultiZ 0:17 0:001 0:11 0:01 0:11 0:01 1:6 0:2
mammals 0:14 0:001 0:089 0:01 0:089 
0:01
1:3 0:3
EPO 0:14 0:001 0:18 0:06 0:18 0:06 0:71 0:2
quality 0:16 0:002 0:11 0:01 0:11 0:01 1:7 0:3
# hits 0:14 0:001 0:10 0:02 0:10 0:02 1:3 0:3
Model 2 HumVar MultiZ 0:17 0:001 0:11 0:008 0:11 0:01 1:4 0:07
mammals 0:14 0:001 0:075 0:01 0:076 
0:009
1:5 0:09
EPO 0:14 0:001 0:15 0:02 0:14 0:02 0:68 0:08
quality 0:16 0:002 0:11 0:01 0:11 0:01 1:4 0:07
# hits 0:14 0:001 0:09 0:01 0:092 
0:009
1:4 0:09
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Table A.8 (continued)
model variant alignment mean time
to fix neutral
variants
mean time
to fix CPDs
mean time
to fix com-
pensations
number
of com-
pensatory
sites
ClinVar MultiZ 0:16 0:005 0:12 0:02 0:13 0:02 1:2 0:1
mammals 0:12 0:005 0:082 0:03 0:083 0:02 1:3 0:1
EPO 0:13 0:006 0:20 0:03 0:15 0:06 0:19 0:2
quality 0:14 0:006 0:12 0:02 0:12 0:01 1:2 0:1
# hits 0:13 0:005 0:10 0:02 0:10 0:02 1:1 0:1
HumVar
/ ClinVar
MultiZ 0:17 0:001 0:11 0:03 0:11 0:02 1:5 0:2
mammals 0:14 0:001 0:082 0:05 0:083 0:03 1:4 0:3
EPO 0:14 0:001 0:18 0:05 0:15 0:07 0:55 0:2
quality 0:16 0:002 0:11 0:02 0:11 0:03 1:5 0:2
# hits 0:14 0:001 0:0990:04 0:0990:04 1:2 0:3
HumVar
/ ClinVar
excluding
ESP
MultiZ 0:17 0:001 0:10 0:03 0:11 0:02 1:6 0:2
mammals 0:14 0:001 0:088 0:05 0:0890:04 1:3 0:3
EPO 0:14 0:001 0:18 0:08 0:14 0:1 0:66 0:3
quality 0:16 0:002 0:10 0:03 0:11 0:02 1:7 0:3
# hits 0:14 0:001 0:10 0:05 0.10 ± 004 1:3 0:3
Model 3 HumVar MultiZ 0:17 0:001 0:170:001 0:078 
0:006
1:4 0:09
mammals 0:14 0:001 0:140:001 0:034 
0:005
1:9 0:2
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Table A.8 (continued)
model variant alignment mean time
to fix neutral
variants
mean time
to fix CPDs
mean time
to fix com-
pensations
number
of com-
pensatory
sites
EPO 0:14 0:001 0:140:001 0:15 0:01 0:71 0:06
quality 0:14 0:002 0:14 
0:002
0:077 
0:006
1:5 0:1
# hits 0:13 0:005 0:130:005 0:059 
0:007
1:5 0:1
ClinVar MultiZ 0:15 0:005 0:150:005 0:11 0:01 1:2 0:1
mammals 0:12 0:004 0:12 
0:004
0:051 0:01 1:4 0:3
EPO 0:13 0:006 0:13 
0:006
0:23 0:04 0:41 0:09
quality 0:14 0:006 0:14 
0:006
0:11 0:01 1:2 0:1
# hits 0:13 0:005 0:130:005 0:0770:02 1:1 0:2
HumVar
/ ClinVar
MultiZ 0:17 0:001 0:170:001 0:0800:02 1:4 0:2
mammals 0:14 0:001 0:140:001 0:037 0:02 1:9 0:6
EPO 0:14 0:001 0:140:001 0:18 0:05 0:63 0:2
quality 0:16 0:002 0:16 
0:002
0:083 0:02 1:5 0:2
# hits 0:14 0:001 0:140:001 0:065 0:02 1:3 0:4
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Table A.8 (continued)
model variant alignment mean time
to fix neutral
variants
mean time
to fix CPDs
mean time
to fix com-
pensations
number
of com-
pensatory
sites
HumVar
/ ClinVar
excluding
ESP
MultiZ 0:17 0:001 0:170:001 0:0860:02 1:5 0:3
mammals 0:14 0:001 0:140:001 0:0490:02 1:6 0:6
EPO 0:14 0:001 0:140:001 0:18 0:06 0:71 0:2
quality 0:16 0:002 0:16 
0:002
0:0860:02 1:6 0:3
# hits 0:14 0:001 0:140:001 0:080 0:03 1:3 0:4
94
Table A.9: BBS4 and RPGRIP1L candidate compensatory sites and in vivo assessment in zebraﬁsh.
injection normal class 1 class 2 total p-value vs MO p-value vs WT rescue
UI Ctrl 338 11 2 351 <0.0001 <0.0001
bbs4MO 87 267 78 432 — <0.0001
bbs4MO+WTRNA 133 39 4 176 <0.0001 —
bbs4MO+N165H 52 91 38 181 0.027 <0.0001
bbs4MO+N160H/N165H 32 44 20 96 0.0078 <0.0001
bbs4MO+N160L/N165H 28 64 24 116 0.4166 <0.0001
bbs4MO+N160R/N165H 26 88 14 128 0.9203 <0.0001
bbs4MO+N160S/N165H 18 52 20 90 0.92 <0.0001
bbs4MO+N163Q/N165H 32 44 16 92 0.0037 <0.0001
bbs4MO+N165H/H366N 26 70 22 118 0.7518 <0.0001
bbs4MO+N165H/H366R 84 32 0 116 <0.0001 0.639
bbs4MO+N165H/H366S 32 90 14 136 0.4666 <0.0001
bbs4MO+N165H/H366T 66 29 12 107 <0.0001 0.019
bbs4MO+H366R 84 16 18 118 <0.0001 0.4839
bbs4MO+H366T 74 14 12 100 <0.0001 0.8875
UI Ctrl 1058 30 3 1091 <0.0001 0.0003
rpgrip1l MO 280 207 76 563 — <0.0001
rpgrip1l MO+WTRNA 134 11 3 148 <0.0001 —
rpgrip1l MO+R937L 32 29 4 65 0.9203 <0.0001
rpgrip1l MO+R94Q/R937L 94 60 6 160 0.0544 <0.0001
rpgrip1l MO+K124R/R937L 72 66 8 146 1 <0.0001
rpgrip1l MO+T128V/R937L 66 66 18 150 0.2117 <0.0001
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Table A.9 (continued)
injection normal class 1 class 2 total p-value vs MO p-value vs WT rescue
rpgrip1l MO+T142I/R937L 13 15 23 51 0.0015 <0.0001
rpgrip1l MO+K179R/R937L 14 28 20 62 <0.0001 <0.0001
rpgrip1l MO+ P189L/R937L 41 12 5 58 0.006 0.0008
rpgrip1l MO+H190Q/R937L 29 20 10 59 1 <0.0001
rpgrip1l MO+ F193L/R937L 45 15 2 62 0.009 0.0017
rpgrip1l MO+A284V/R937L 31 22 13 66 0.7642 <0.0001
rpgrip1l MO+K335T/R937L 26 20 10 56 0.7401 <0.0001
rpgrip1l MO+D367N/R937L 25 22 7 54 0.729 <0.0001
rpgrip1l MO+V421I/R937L 21 17 7 45 0.8065 <0.0001
rpgrip1l MO+K443N/R937L 21 22 7 50 0.3681 <0.0001
rpgrip1l MO+ L447F/R937L 29 17 5 51 0.4062 <0.0001
rpgrip1l MO+V481E/R937L 33 18 4 55 0.1897 <0.0001
rpgrip1l MO+R535Q/R937L 27 18 9 54 0.9203 <0.0001
rpgrip1l MO+H563Q/R937L 31 24 13 68 0.6033 <0.0001
rpgrip1l MO+V647I/R937L 35 25 14 74 0.7913 <0.0001
rpgrip1l MO+R649Q/R937L 25 17 10 52 0.9203 <0.0001
rpgrip1l MO+ E689D/R937L 26 19 12 57 0.6468 <0.0001
rpgrip1l MO+ I717V/R937L 24 14 10 48 0.9203 <0.0001
rpgrip1l MO+Q903K/R937L 17 24 8 49 0.0614 <0.0001
rpgrip1l MO+R937L/L958V 25 16 12 53 0.8231 <0.0001
rpgrip1l MO+R937L/R961T 42 7 8 57 0.0009 0.004
rpgrip1l MO+R937L/D986S 24 19 13 56 0.3994 <0.0001
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Table A.9 (continued)
injection normal class 1 class 2 total p-value vs MO p-value vs WT rescue
rpgrip1l MO+R937L/P1016S 20 20 20 60 0.0226 <0.0001
rpgrip1l MO+R937L/K1020E 26 15 15 56 0.7401 <0.0001
rpgrip1l MO+R937L/I1092V 26 22 15 63 0.2542 <0.0001
rpgrip1l MO+R937L/Q1162R 19 24 12 55 0.0444 <0.0001
rpgrip1l MO+R937L/K1215Q 32 21 15 68 0.7773 <0.0001
rpgrip1l MO+R937L/V1257I 21 25 11 57 0.0859 <0.0001
rpgrip1l MO+R937L/L1272I 26 17 18 61 0.3566 <0.0001
rpgrip1l MO+ P189L 68 18 6 92 <0.0001 0.0012
rpgrip1l MO+ F193L 54 20 4 78 0.0019 0.0001
rpgrip1l MO+R961T 76 26 6 108 <0.0001 <0.0001
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Table A.10: Head sizemeasurement summary and p-values for btg2, nos2a/bMO-injected embryos. n/a, not applicable;
MO,morpholino; UI, uninjected.
Injection
Number
of Em-
bryos
Distance from
forebrain to
hindbrain
p-value
vs. UI
control
p-value
vs. btg2
MO
p-value
vs.
BTG2
WT
rescue
Mean
dis-
tance
(μm)
Standard
devia-
tion
Control 79 623.06 27.16 n/a
btg2MO 73 566.51 36.44 <0.0001 n/a
btg2MO+ BTG2WTmRNA 54 614.95 30.68 0.11 <0.0001 n/a
btg2MO+ BTG2 p.V141MmRNA 72 585.27 28.23 <0.001 0.0006 <0.0001
BTG2WTmRNA 49 626.32 24.37 0.50 <0.0001 n/a
BTG2 p.V141MmRNA 72 613.60 26.62 0.30 <0.0001 n/a
nos2aMO 77 615.06 31.29 0.40 n/a n/a
nos2bMO 53 608.46 30.85 0.15 n/a n/a
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Table A.11: BTG2 candidate compensatory sites and in vivo quantiﬁcation of proliferating cells in the zebraﬁsh head as
determined by phospho-H3 immunostaining.
BTG2 Injection
Average
cell
count
StdDev
Number
of em-
bryos
p-value
vs MO
p-value
vs WT
rescue
UI Ctrl 386.65 55.85 26 <0.0001 0.0104
btg2MO 234.96 69.00 26 — <0.0001
MO +WTRNA 357.27 61.73 22 <0.0001 —
MO+V141M 220.86 65.75 14 0.3759 0.0005
MO + V141M/G6R 206.44 58.38 16 0.2493 <0.0001
MO + V141M/G40R 247.15 57.55 20 0.1496 <0.0001
MO + V141M/R80K 378.05 71.87 22 <0.0001 0.2004
MO + V141M/Q94R 268.91 47.49 11 0.2249 0.0048
MO + V141M/S98R 250.92 87.87 13 0.3804 0.0044
MO + V141M/L128V 368.24 95.68 17 <0.0001 0.0969
MO + V141M/A130T 234.80 61.20 10 0.2677 0.0018
MO + V141M/C132Y 240.33 59.26 12 0.3023 0.0002
MO + V141M/L142M 227.20 29.91 10 0.1108 <0.0001
MO +R80K 326.20 60.63 10 0.0048 0.2091
MO + L128V 334.75 46.65 12 <0.0001 0.4383
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(a)Distributions of neutral variants.
Figure A.1: Different alignmentmethodologies with HumVar and ClinVar produce qualitatively similar alignments. A–
B) Distributions of missense variants annotated as neutral (A) or pathogenic (B) in the HumVar and ClinVar datasets,
with each of the ﬁve alignment strategies described in the text (MultiZ unﬁltered, MultiZmammals-only, EPO,MultiZ
with alignment quality ﬁlter, MultiZ with>1 sequence ﬁlter). All distributions are qualitatively similar. Compare to
Figures 2C–D of themain text.
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(b)Distributions of pathogenic variants.
Figure A.1: (continued)
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Figure A.2: Evaluation of btg2 and nos2a/bmorpholinos (MO)s. A, B, C) Schematic of the D. rerio btg2, nos2a and
nos2b loci. Blue boxes, exons; dashed lines, introns; white boxes, untranslated regions; red boxes, MOs; ATG indicates
the translational start site; arrows, RT-PCR primers; number indicates the targeted exon. D, E) Agarose gel images of
nos2a/bRT-PCR products.
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Figure A.3: Protein domain structure of functionally tested human disease genes. A) Schematic of BBS4 (519 amino
acids) is depicted with eight tetratricopeptide (TPR) domains (yellow); B) RPGRIP1L (1315 amino acids) has multiple
coiled-coil domains (green rectangles) and two Protein kinase C conserved region 2 (C2) domains (green hexagons);
and C) BTG2 (158 amino acids) has one BTG1 domain (purple pentagon). Disease-causing alleles are shownwith red
stars; complementing alleles are representedwith blue stars; amino acid number scale in increments of 100 is shown
below each schematic.
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